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The germ theory of disease, which dictates that microorganisms colloquially
referred to as “germs” can invade humans or other hosts and cause disease, has remained
the dominant conceptualization of infectious disease since the late nineteenth century.
Since that time, growing appreciation for the extent of subclinical infections, that is,
infections where the germ is detectable in its host without causing overt disease, and the
Mendelian inheritance patterns of some infectious diseases have reinvigorated the study of
the human genetic basis of infectious disease. This theory, so far demonstrated for a
number of bacterial, fungal, and viral infections, holds that germs are a necessary but not
sufficient condition for infectious disease with susceptibility determined by the genetics of
individual members of the host species.
In the first part of this thesis, I describe a child with inherited, complete interferon
regulatory factor-9 (IRF9) deficiency who suffered from a life-threatening pulmonary
influenza infection. This discovery adds to the growing body of evidence which indicates
that susceptibility to severe primary infections, even from common pathogens such as
influenza virus, is genetically determined. IRF9 is a critical regulator of innate anti-viral
immunity in the type I and III interferon (IFN) signaling pathways, which share many
signaling proteins. Consistent with this role, I show that the patient’s cells had drastically

reduced responses to type I IFN which led to increased influenza virus replication. Profiling
the transcriptome of the patient’s cells following stimulation with type I IFN revealed that
the transcriptional response to IFN is not completely abolished in the patient’s cells.
Indeed, the patient’s cells induced a small but partially overlapping set of antiviral
mediators when compared to transcriptional responses from healthy control cells.
Unfortunately, type III IFN signaling could not be directly assessed as fibroblasts, the cell
line used throughout for viral and biochemical analyses, do not express the type III IFN
receptor. These data demonstrate that IRF9 deficiency disturbs type I, and likely type III,
IFN signaling, and that this deficiency underlies the patient’s severe influenza infection.
In the second part of this thesis, I describe the first cases of inherited IFN IFNα/b
receptor-1 (IFNAR1) deficiency in children who suffered severe complications following
vaccination with attenuated viral vaccines but who were otherwise healthy. IFNAR1 is one
of the two subunits that form the receptor for type I IFNs, and I show that type I IFN
signaling is abolished in the patients’ cells. Consistent with a defect in type I IFN signaling,
the patients’ cells exhibit a profound susceptibility to all viruses tested in vitro, in contrast
with the patients’ specific and, compared to other primary immunodeficiencies, relatively
mild phenotype. This susceptibility was dependent on the absence of a functional IFNAR1
receptor, which we established through complementation experiments. Taken together,
these two studies interrogate the functions of the type I and III IFN pathways that are
critical for human immunity to viral diseases and provide evidence for an underappreciated
non-redundancy within these pathways.
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Chapter 1: Introduction

1

The ability of each organism to differentiate self from non-self is fundamental to
the organism’s continued survival and necessary for the development of even the most
rudimentary immune system. This differentiation may occur at a cellular or multicellular
level, or at increasingly subtle subcellular levels, including the proteome, the
transcriptome, or the genome of a given cell1. Following identification of a non-self
element, be it a pathogen or simply a mis-translated protein, an organism must modify its
behavior to neutralize the presumed threat, redirecting its energy and resources, at least
momentarily, to this end. Yet it is not advantageous for an organism to remain in this state
while it could be more aggressively pursuing its other biological imperatives. The
diminution of the immune response is therefore equally important to a well-functioning
immune system and, together with the stochastic nature of infection, gives rise to the
periodic immunological crescendo-decrescendo of transient infection with which we are
all familiar.
Similarly, this contrapuntal dance of a pathogen with its host’s immune response
defined scientists’ early understanding of infectious disease in the modern era, forming the
basis of the germ theory of disease. Beginning in the mid-nineteenth century, the germ
theory, which held that microorganisms called “germs” or pathogens invaded a host and
caused disease in doing so, began to supplant the miasma theory of disease, which held
that many diseases were caused by noxious “bad air”. This shift was inaugurated in 1865
with Louis Pasteur’s work on silk worms and culminated in Robert Koch’s isolation of the
causative agent of tuberculosis in 18822. Studying two diseases which killed silk worms
and disturbed the cloth industry in France, Pasteur connected his earlier work on bacterial
fermentation with these diseases and hypothesized that microorganisms were responsible
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for the worms’ illnesses. Furthermore, based on microscopic examination of the worms’
eggs, Pasteur developed an effective mechanism of prophylaxis4. These victories were
inconclusive, however, as they had not offered true proof that the pathogens were
responsible for the observed diseases; a more rigorous demonstration was later
accomplished by Koch.
Following his work on the anthrax bacillus, Koch travelled to London and began
research on tuberculosis, the most feared and deadly disease of the time5. Once he had
pioneered new methods of tissue staining, Koch was quickly able to isolate a bacterium
from symptomatic patients, yet he needed more evidence to prove that the bacterium
caused the disease5. This goal led him to develop four postulates that must be met to
establish causality in bacterial infections6. These postulates required that the bacteria and
disease coincide in symptomatic patients, that the bacteria be isolated in pure culture, and
that inoculation of healthy subjects with the isolated bacteria would lead to the
development of disease5. Following these criteria, Koch discovered that the bacteria
isolated from tuberculosis patients would form tubercles upon inoculation into animals that
were proportional to the size of the bacterial inoculum, thereby establishing that the
bacillus was the generative agent of tuberculosis6. He presented these findings in 1882 to
great acclaim and international fame. With this, the germ theory of disease had effectively
supplanted the miasma theory as the dominant explanation of disease.
Yet it was not a perfect explanation; violations of Koch’s postulates were known
even to Koch at the time, and more significant objections would be raised in the coming
years7. In particular, Charles Nicolle’s work documenting inapparent (subclinical)
infections and Clemens Von Pirquet’s development of the tuberculin skin test,
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demonstrated that known pathogens could be present in humans without any evidence of
disease2,8,9. These issues may be considered collectively as problems of interindividual
variability in response to infection. Human geneticists including Archibold Garrod and
Karl Pearson, among others, proposed a germline theory of infectious disease to explain
this variability and provided strong evidence in this direction2. Epidemiological studies,
for example, showed that appendicitis segregated as an autosomal dominant trait in a
number of multiplex kindreds10. More convincingly, elegant twin studies on tuberculosis
were carried out, which demonstrated concordance rates of 80% in monozygotic twins, but
only 20% in dizygotic twins11,12. Even more broadly, early death from infection has been
shown to correlate highly with the death of the individual’s biological, but not adoptive
parents,

from

infection13.

The

contemporaneous

description

of

Bruton’s

agammaglobulinemia, the first primary immunodeficiency (PID), established the existence
of Mendelian inborn errors of immunity14. However, the gap between the broad infectious
phenotypes of the first immunodeficiencies and the pathogen-specificity of interindividual
variability was sizable.
The advent of modern molecular biological and genetic techniques has enabled the
dissection of additional Mendelian infectious diseases such as Mendelian susceptibility to
mycobacterial disease (MSMD)15,16. MSMD is characterized by susceptibility to poorly
virulent mycobacterial species (most commonly the live Bacillus Calmette-Guérin [BCG]
vaccine) and, more rarely, intramacrophagic pathogens such Salmonella17. Following the
identification of autosomal recessive (AR) complete interferon-γ receptor-1 (IFN-γR1)
deficiency as the first genetic etiology for MSMD, the search for genetic bases to infectious
diseases was broadened to include additional defects in IFN-γ signaling in MSMD, as well
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as defects in non-mycobacterial infections18–21. In 2002, the work of Gerard Orth on
epidermodysplasia verruciformis (EV), a dermatologic disease caused by infection with
nonpathogenic human b-papillomaviruses (b-HPV), demonstrated that viral diseases could
also be explained by single gene errors of immunity22. Although a number genes
underlying EV have been described, the molecular mechanism of disease remain elusive
for its three primary etiologies, biallelic null mutations of EVER1, EVER2, and CIB1
(calcium and integrin binding protein-1), limiting the extent to which the insights provided
by these studies can be generalized to other viral diseases22,23. More broadly applicable
lessons would be learned from the study of herpes simplex encephalitis (HSE).
HSE is a rare complication of infection with herpes simplex virus-1 or -2 (HSV-1
or -2, respectively), with HSV-1 being the more common cause of disease24. HSV-1 is a
nearly ubiquitous pathogen and most humans experience

infection

without

adverse

consequences during their life25. Despite the sparsity of multiplex kindreds suffering from
HSE, a retrospective survey revealed that 12% of French children with the disease were
born to consanguineous parents26. Together, these data suggested that HSE could be caused
by monogenic inborn errors of immunity, with incomplete clinical penetrance producing
the observed non-Mendelian pattern of inheritance. Working off earlier hints that defects
in type I or III IFN signaling may underlie HSE, Casrouge et al. and Zhang et al. each
identified two HSE patients with defects in either UNC93-B or Toll-like receptor-3
(TLR3), both of which are critical for the production of type I and III IFNs following
recognition of double-stranded RNA (dsRNA)27–31. Both type I and type III IFNs are
secreted signaling proteins critical for defense against viral pathogens32,33. Furthermore,
their mechanisms of induction and downstream signaling components (outside of the IFN
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molecules themselves and the specific receptors to which they bind) are largely
overlapping (FIGURE 1.1)33. Further studies on children suffering from HSE revealed a
number of associated deficiencies that underlie the disease, including deficiencies in
TANK binding kinase-1 (TBK1), TNF receptor associated factor-3 (TRAF3), TIRdomain-containing adapter-inducing IFN-b (TRIF), or IRF334–37. Heartened by the success
of these efforts, geneticists have recently worked to expand the list of viral diseases known
to result from single-gene inborn errors in immunity.
Although the prevailing wisdom suggests that susceptibility to most severe viral
infections is a polygenic trait mediated by the combined effect of numerous loci, an
increasing number of viral diseases have been shown to have monogenic etiologies38. First,
Byun et al. published two papers providing genetic explanations of Kaposi sarcoma, a
human herpesvirus-8 (HHV-8)-induced tumor which develops in a small subset of infected
individuals39,40 . Significantly, the defects described in these papers, stromal interaction
molecule-1 (STIM1) deficiency and OX40 deficiency, resulted in impoverished T cell
compartments; the clinical distinctiveness of KS and HSE patients appropriately reflected
in the mechanistic independence of the pathways uncovered in the genetic analysis of each
condition. Next, in 2015, Ciancanelli et al. described autosomal recessive IRF7 deficiency
in a child suffering from a life-threatening episode of acute respiratory distress syndrome
(ARDS) following primary infection with influenza virus41. IRF7 is a transcription factor
critical for induction of type I and III IFNs and is constitutively expressed in plasmacytoid
dendritic cells (pDCs), the major type I and III IFN-producing cells42,43. The production of
type I and III IFNs was severely diminished in the patient’s leukocytes, and the patient’s
cells also replicated much higher levels of influenza virus in vitro41,44. Both phenotypes
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could be rescued by complementation with wild-type (WT) IRF7, or by treatment with
exogenous IFN in the case of the viral replication defect specifically41. This work
demonstrated that common, isolated, viral diseases of childhood that were not previously
thought to be genetic could be caused by monogenic errors of immunity.
Following this, Lamborn et al. characterized MDA5 deficiency in a child with
recurrent human rhinovirus (HRV) infections45. Similar to TLR3, MDA5 senses dsRNA
produced as viral byproducts or intermediates, although TLR3 monitors the endosomal
compartment while MDA5 surveils the cytoplasm46,47. Interestingly, although this patient
also suffered from influenza A virus (IAV) and respiratory syncytial virus (RSV)
infections, reintroduction of WT MDA5 could not restrict IAV or RSV replication in vitro,
although it did restrict HRV replication in this setting45. Together, these data provide
evidence that MDA5 deficiency underlies susceptibility to HRV, a pervasive viral
pathogen. More recently, Belkaya et al. described a patient with fulminant viral hepatitis
and inherited IL-18 binding protein (IL-18BP) deficiency48. The authors showed that in the
absence of IL-18BP, excessive natural killer (NK) cell activation led to unchecked killing
of hepatocytes in vitro, again implicating a distinct cell type and signaling pathway in a
discrete viral disease48. Additional work has focused on defects in the type I and/or type III
IFN signaling pathways themselves, in particular on defects in signal transducer and
activator of transcript-2 (STAT2), which is common to both type I and III IFN signaling
pathways, and defects in IFNα/b receptor-2 (IFNAR2), which is utilized only by type I
IFNs49–52. These studies, largely carried out by Sophie Hambleton’s group in the UK,
outline a clinical phenotype characterized by severe, adverse reaction to measles, mumps,
and rubella (MMR) vaccination and, for patients deficient in STAT2, frequent infection
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with common environmental pathogens, such as HRV and RSV49–52. This work, while also
expanding the catalog of viral diseases shown to have a genetic etiology, further draws into
question how defects in these two pathways could result in multiple, seemingly discrete,
clinical phenotypes.
Despite the mounting evidence that isolated, severe viral infections can result from
single gene inborn errors of immunity in a manner contingent on the pathway disrupted,
the centrality of type I and III IFN signaling to HSE, IAV, HRV, RSV, and MMR immunity
suggests that there may be an underappreciated sensitivity within this pathway to explain
these divergent clinical presentations. If so, we might further hypothesize that undescribed
defects within the type I and/or III IFN signaling pathways may serve as genetic etiologies
for viral diseases that are not currently considered to be genetic. In this thesis, two
additional studies involving patients with genetically determined susceptibility to viral
infections are presented as first-steps to addressing these hypotheses.
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Figure 1.1 Signal transduction in the type I, II, and III IFN signaling pathways.
Binding of IFN with the appropriate receptor results in activation of a JAK-STAT
signaling cascade, leading to the phosphorylation of various STAT proteins and the
formation of transcription factors such as ISGF3 (a heterotrimer of pSTAT1,
pSTAT2, and IRF9) and GAF (a pSTAT1 homodimer). These bind to their
corresponding ISRE or GAS DNA sequences and initiate transcription of various
interferon stimulated genes (ISGs). Image taken from Dussurget et al.53
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Chapter 2:
Inherited IRF9 deficiency as a genetic etiology of life-threatening influenza
infections1

1

Chapter 2, and portions of the materials and methods, are edited from: Hernandez, N. et al. Lifethreatening influenza pneumonitis in a child with inherited IRF9 deficiency. J. Exp. Med. (2018).
doi:10.1084/jem.20180628
This manuscript can be found at http://jem.rupress.org/content/215/10/2567. Author contributions are
available in the acknowledgements section of this thesis, in addition to being more fully explicated in the
manuscript itself.
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Introduction
Influenza virus is a common human pathogen that typically causes self-limiting
respiratory disease in children, but can also lead to severe fulminating illness with
pneumonia and an acute respiratory distress syndrome54. Seasonal epidemics and
pandemics demonstrate that virus strain differences can influence the frequency and
severity of infections, yet these differences cannot explain the inter-individual variability
in a population infected by an identical virus55–57. Furthermore, almost no risk factors for
severe influenza infections in children have been identified. The few risk factors that have
been identified generally include acquired comorbidities, such as chronic pulmonary or
cardiovascular disease, and old age58–60. Consequently, the pathogenesis of life-threatening
pulmonary influenza in children remains largely unexplained61. In contrast to focusing on
the genetics of the influenza virus itself, the recent work of Ciancanelli et al. established
AR, complete IRF7 deficiency in humans as the first genetic etiology for life-threatening
influenza ARDS in an otherwise healthy patient41. This work demonstrated that IRF7 is
critical for the amplification of type I and type III IFNs in human pDCs, peripheral blood
mononuclear cells (PBMCs), and induced pluripotent stem cell (iPSC)-derived pulmonary
epithelial cells. The inability of the patient’s cells to induce type I and III IFNs likely
underlies their susceptibility to influenza. GATA2 haploinsufficiency has also been
described to result in severe influenza infections, although these patients typically have
multiple infections and abnormal development of various myeloid and lymphoid subsets,
including pDCs62–64. Three GATA2 deficient patients experienced severe influenza
episodes at ages 18, 31, and 54, but influenza was the first infection requiring
hospitalization for only one patient62–64. Although the mechanism by which GATA2deficiency results in susceptibility to severe influenza infections is unknown, the lack of
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pDCs in these patients is suggestive, due to their high basal expression of IRF7 and their
efficacy in inducing IFNs65,66. Lastly, IAV-ARDS has recently been described in three
kindreds with TLR3-deficiency, further supporting the centrality of type I and III IFNs to
this disease45,67,68. Perplexingly, however, inborn errors of MDA5-dependent production
of IFNs are not known to underlie severe influenza. Only one such patient has been
comprehensively studied, although nine other putative patients have been identified45,69,70.
It is therefore possible that future studies will uncover MDA5 deficiency in patients with
IAV-ARDS. Similarly, patients with IL-10RB deficiency, who are therefore unresponsive
to type III IFN, have not been shown to suffer from severe influenza infections, suggesting
that type I IFN may be more relevant than type III IFNs in immunity to influenza virus71,72.
Counter to this hypothesis, STAT1-, STAT2-, Janus kinase 1- (JAK1-), Tyrosine kinase 2(TYK2-), and IFNAR2-mutated patients, with defective type I IFN responses, were also
not reported to suffer from severe influenza infections49–52,73–75. In addition, severe
influenza has not been reported in any of the patients suffering from any of the >350 other
known inborn errors of immunity, including patients lacking T cells, or B cells, or both76,77.
Taken together, these data suggest that the human TLR3-, GATA2-, and IRF7-dependent
production of type I and/or type III IFNs is essential for protective immunity against
influenza virus.
Mice either homozygous for an Irf7 null allele or heterozygous for a Gata2 null
allele have also been characterized, as well as numerous strains deficient in TLR3. Gata2
+/- mice have not been studied for infectious diseases, although they possess dramatically
reduced pDC counts, as research has instead focused on hematopoietic and vascular
integrity78–80. Viral susceptibility has been studied in Irf7 -/- mice, which display reduced
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induction of IFN-a/b following either viral infection or stimulation with synthetic TLR
agonists,

as

well

as

increased

vulnerability

to

infection

with

HSV-1

or

encephalomyocarditis virus (EMCV)81,82. Furthermore, Irf7 was identified as one of 25
differentially expressed genes (DEGs) between C57BL/6J and DBA/2J mice infected with
IAV that overlapped with DEGs previously identified to be important for IAV replication
in siRNA screens83. Continuing this work, the authors compared Irf7 -/- mice with Irf3 -/mice and double knockouts and found that, while deletion of IRF3 had a moderate impact
on IFN expression, absence of IRF7 abolished IFN-α production84. Consistent with
Ciancanelli et al., IFN-b induction was modestly preserved in some cell types in the
absence of IRF7, although this induction was dependent on the presence of IRF384.
Furthermore, Irf7 -/- mice infected with IAV experienced greater morbidity and mortality
than healthy control mice83. Unfortunately, the C57BL/6 parental strain used to generate
the mice in these studies does not contain a functional Mx1 allele85,86. Due to the critical
role of Mx1 in immunity to influenza virus in mice, however, these data, and those from
many other mouse studies of IAV, merit cautious reexamination85–87. Buttressing the
hypothesis that type I IFN is essential for control of IAV in mice, however, Ifnb1 -/- mice
in an Mx1-positive background were significantly more sensitive to IAV than mice with
WT Ifnb1 alleles were88. Additional studies, also performed in an Mx1-replete background,
have found IFNAR1, TLR7, and MyD88 signaling to be critical for defense against
influenza virus88,89. Mice with impaired type III IFN immunity have been shown to display
marginally elevated influenza virus replication relative to WT mice, and to be
hypersusceptible to influenza virus when type I IFN signaling was also ablated90. A more
recent study has shown that mice lacking a functional type III IFN receptor (Ifnlr -/-) shed
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significantly more viral particles and transmitted the infection more easily to naive mice
than did WT mice or mice defective in type I IFN signaling, suggesting some nonredundancy in these two pathways during IAV infection91. These data thus suggest that
type I and type III IFNs may have non-overlapping roles and may therefore both be critical
for immunity against influenza virus in humans and mice. We hypothesized that defects of
type I and/or type III IFN production or signaling, other than GATA2 and IRF7
deficiencies, may underlie severe influenza infections in otherwise healthy individuals. To
test this hypothesis, we analyzed the whole-exome sequencing data of 20 children who
suffered severe influenza infections, focusing especially on genes related to type I and/or
III IFN.

Results
Homozygosity for a splice site mutation in IRF9
We studied a seven-year old girl (patient, P) who was born to first-cousin Algerian
parents and who was hospitalized for a severe infection with IAV requiring mechanical
ventilation and Tamiflu treatment at age two (Fig. 2.1A). In addition, she had a history of
recurrent benign bronchiolitis, biliary perforation following MMR vaccination at 1 year of
age, and recurrent fevers without a causative pathogen identified. P also was infected with
RSV within her first year of life, leading to hospitalization but not admission to the
intensive care unit (ICU). To confirm her clinical course, we first performed VirScan
analysis on P’s plasma, taken at age two, seven weeks prior to intravenous immunoglobulin
(IVIg) administration yet after disappearance of maternal antibodies, to determine her
history of viral infections92. As well as confirming P’s IAV and RSV infections, we
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detected specific antibodies against viruses including HSV-1, human cytomegalovirus
(HCMV), HRV, and enterovirus in her plasma (Fig.2.S1). Following her recovery from
IAV infection, P also experienced adenovirus and parainfluenza virus (PIV) infections for
which she was admitted to the hospital, although neither required admission to the ICU.
Both infections were confirmed by VirScan. We performed whole exome sequencing
(WES) on this kindred (trio design) and identified a c.991G>A mutation in IRF9, which
encodes a critical element of the type I and III IFN signaling pathways, IRF993–95. Sanger
sequencing confirmed that the patient was homozygous for this mutation while both her
parents and her healthy sister were heterozygous (Fig. 2.1B). Additionally, the patient’s
exome showed 6.8% homozygosity, consistent with her parents being first cousins96. This
segregation is therefore consistent with an AR pattern of inheritance with complete
penetrance97.
P’s variant, which occurs in the final nucleotide of exon 7, is predicted to disrupt
the essential splice donor site at this location, while also mutating an aspartic acid to
asparagine at amino acid (aa) 331 (p.D331N). Because of the uncertainty in the ultimate
consequences of this mutation on IRF9 structure, we will presently refer to this allele by
its effect on the cDNA, c.991G>A. Computational prediction of the deleteriousness of this
mutation by calculation of its combined annotation dependent depletion (CADD) score
indicated that it was likely to be deleterious, since its CADD score was well above the
mutation significance cutoff (MSC) (Fig. 2.1C)98,99. Significantly, this variation was absent
from public databases, including 1,000 genomes, Bravo, and GnomAD (Genome
Aggregation Database) – a database that encompasses the ExAC (exome aggregation
consortium) database. We also searched P’s exome for other homozygous or compound
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heterozygous non-synonymous rare variations (MAF <0.01), and identified such mutations
in 19 other genes. None of these other genes are known to be disease causing. Two
missense mutations were identified in genes encoding topoisomerase 2A (TOP2A) and 5’3’ exoribonuclease 2 (XRN2), the only two genes connected to known PID genes in a
connectome analysis100. The only three genes that carried homozygous variations predicted
to be loss-of-function were unrelated to PIDs: disheveled binding antagonist of beta catenin
2 (DACT2), ENTH domain containing 1 (ENTHD1), and Forssman glycolipid synthaselike protein (GBGT1). Overall, these data suggested that P had AR IRF9 deficiency and
consequently, that homozygosity for c.991G>A was the most plausible genotype
responsible for her severe influenza infection.
Population genetics of human IRF9
IRF9 encompasses 9 exons, 8 of which are protein-coding (exons 2 through 9) (Fig.
2.1D). To assess how commonly IRF9 is mutated and its function altered among healthy
people, we next calculated the gene damage index (GDI) of IRF9, and its McDonaldKreitman neutrality index101. Although IRF9’s GDI is moderate (1.16), its McDonaldKreitman neutrality index of 0.088 indicates that the gene is under negative selection101.
Examining GnomAD for the presence of comparable variants, only one non-synonymous
exonic variant and two intronic variants were found in homozygosity: c.381G>C:p.Q127H,
c.991+119T>G, and c.991+189C>A, with minor allele frequencies (MAFs) of 0.001, 0.01,
and 0.001, respectively. Individuals were identified carrying all three variants from our inhouse WES cohort of 4,892 patients with severe infectious diseases. The two intronic
variants found in the heterozygous state in multiple individuals and the Q127H variant
found in the homozygous state in one individual. Only one of the three variants was
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predicted to alter protein sequence and may therefore impact IRF9 function, while the latter
two mutations occur in an intron, are not predicted to create a splice site, and actually do
not utilize or create an alternative splice site (Fig. 2.S2). The individual homozygous for
the Q127H allele in our cohort suffered from a fungal infection of the central nervous
system and had no history of viral disease. In addition to the variants found in gnomAD,
our own WES cohort contained a third homozygous non-synonymous variation in IRF9,
c.874C>T:p.R292C (Fig. 2.1C). Unfortunately, the individual harboring this variant also
bore a homozygous mutation in HOIL1 that resulted in chronic autoinflammation, invasive
bacterial infections and muscular amylopectinosis102. In addition to these conditions,
however, he also experienced profound HCMV viremia102. Combined, homozygosity for
any of these three variants (Q127H, R292C, and c.991G>A) is predicted to affect fewer
than 1 in 10,000 individuals. Thus, even if all variants produced life-threatening influenza
infections, the incidence of such infections would not be higher than is currently observed.
Consistent with these variants potentially altering IRF9 structure and function, their CADD
scores were all above the MSC (Fig. 2.1C)99. Consequently, we aimed to assess the impact
of P’s variant on IRF9 function, as well as the function of the two other IRF9 missense
alleles found in homozygosity in rare individuals from the general population (Q127H) or
our in-house cohort (R292C).

Expression of a truncated mRNA and protein by the mutant IRF9 allele
We hypothesized that the c.991G>A mutation would produce an aberrantly spliced
IRF9 transcript, as it occurs in an essential splice site at the terminal nucleotide of exon 7.
To test this, we transiently transfected a segment of P’s IRF9 allele encompassing introns
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5 through 8, as well as a segment from an identical region of a WT allele, into IRF9
deficient U2A fibrosarcoma cells, a gift from Sandra Pellegrini (Fig. 2.S3)103. We then
sequenced the resulting cDNAs, detecting two transcripts produced from P’s IRF9 allele
(Fig. 2.1E). The dominant transcript exhibited absence of exon 7 with normal exons 6 and
8. The second, minor transcript also lacked exon 7 but utilized an alternative splice acceptor
site in exon 8. The WT allele, however, produced 4 different transcripts two of which were
rare, with the other two being roughly equally common. One of the more common
transcripts demonstrated correct splicing at exons 6/7 and 7/8 junctions while the other
common product lacked exon 7 but correctly utilized the splice sites in exons 6 and 8. Of
the two rare transcripts, one was a product of an alternative splice acceptor site in exon 7,
whereas another resulted from use of an alternative splice acceptor site in intron 5 (Fig.
2.1E). Sequencing cDNAs generated from IRF9 transcripts present in healthy control BLCLs (EBV-transformed B lymphoblastoid cell lines) and SV40 large T antigen
immortalized fibroblasts (SV40-F cells) revealed only correctly spliced transcripts,
suggesting that the other transcripts observed in the overexpression setting are not present
endogenously. Additionally, sequencing cDNAs from P’s B-LCLs and SV40-F cells
revealed only transcripts lacking exon 7, and none that would result in a D331N mutation
in the protein (Fig. 2.1F). The deletion of exon 7 is in-frame and does not introduce a
premature stop codon. This mutant protein (and the corresponding allele) will thus now be
referred to as IRF9-Δex7. Next, we evaluated IRF9 mRNA levels in P’s PBMCs and SV40F cells. Consistent with the cDNA sequencing results, only IRF9 transcripts lacking exon
7 were detected in P’s PBMCs by quantitative reverse transcription polymerase chain
reaction (qRT-PCR), while a reduced number of full-length IRF9 transcripts were detected
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in both individuals harboring the c.991G>A variant in proportion to the dosage of this allele
(Fig. 2.2A). Western blot (WB) analysis of P’s cells and those of her mother with a
polyclonal antibody (pAb) revealed a truncated IRF9 species in both individuals’ cells (Fig.
2.2B). Significantly, full-length IRF9 was not detected in P’s cells (Fig. 2.2B). The
molecular weight (MW) of the truncated protein we detected is roughly 12 kDa below the
MW of WT IRF9, consistent with a lack of exon 7 (142 amino acids). This region forms a
substantial portion of the IRF-association domain (IAD) which is critical for the interaction
of STAT proteins with IRF9 (Fig. 2.1D)104. Overall, these findings established that the
patient suffered from AR IRF9 deficiency.

Normal activation of STAT1 and STAT2 in cells expressing mutant IRF9
We then set out to define the consequences of IRF9 deficiency, first by examining
the function of the mutated IRF9 protein, focusing initially on the proximal signaling
events immediately downstream of the type I IFN receptor. To this end, plasmids encoding
IRF9-Δex7, the other two missense mRNAs found in homozygosity in public databases or
our cohort (Q127H, R292C), or WT IRF9 were stably transfected into U2A cells and IRF9
expression was verified by WB (Fig. 2.2C). K81R and R292Q IRF9 alleles were included
throughout the study since they have been reported to be loss-of-function in in vitro
studies105. All IRF9 alleles were expressed at comparable levels, indicating that these
variants can be normally transcribed and translated, and that the encoded mRNAs and
proteins are stable in these conditions (Fig. 2.2C). Consistent with this, stable transfection
of WT IRF9 in P’s SV40-F cells restored normal expression of IRF9, suggesting that the
poor expression of IRF9 in her cells was due to the homozygous Δex7 mutation in IRF9
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itself, rather than other mutations also present within her cells (Fig. 2.2D). Following
stimulation with IFN-α2b, a type I IFN, P’s cells normally phosphorylated STAT1 and
STAT2, suggesting that IRF9 is dispensable for this process (Fig. 2.2B). These data are
consistent with previous reports that STAT1 and STAT2 phosphorylation occurs
immediately following type I IFN-stimulation of U2A cells106,107. We therefore conclude
that the truncated IRF9 protein produced by the IRF9-Δex7 allele does not affect IFNARproximal signaling, at least in SV40-F cells and U2A fibrosarcoma cells.

Abolished activation of ISGF3 in cells expressing mutant IRF9
STAT1, STAT2, and IRF9 jointly form the ISGF3 transcription factor in an
interaction mediated by IRF9’s IAD104. IRF9 is also predicted to participate in the binding
of the heterotrimeric complex to DNA94,108–110. We therefore hypothesized that IRF9-Δex7
may be unable to engage with STAT1 and STAT2 to form a functional ISGF3 due to the
absence of a complete IAD104. To address this hypothesis, we fractionated nuclear and
cytoplasmic compartments of P’s SV40-F cells to determine the localization of P’s IRF9
protein under basal conditions (Fig. 2.2E). Consistent with the presence of an NLS in the
N-terminus of IRF9, IRF9 was visible in the nucleus even under basal conditions. Although
expressed at substantially lower levels than the full-length protein, IRF9-Δex7 was also
detectable in the nucleus. To test for the presence of any functional ISGF3 complexes, we
examined the ability of U2A cells transfected with the various IRF9 alleles to drive
luciferase transcription from an IFN-stimulated response element (ISRE) promoter.
Significantly, no ISRE-driven luciferase was detectable in cells transfected with IRF9Δex7 but normal luciferase levels were observed when transcription was driven by a
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promoter containing a gamma activation sequence (GAS), when compared with the
responses of healthy controls (Fig. 2.2F). In contrast, the Q127H and WT variants were
able to induce transcription of luciferase from both ISRE and GAS promoters while both
R292Q and R292C variants displayed an intermediate phenotype, with roughly 50%
activity compared with the WT allele. Taken together, these data strongly suggest that P’s
IRF9 variant, Δex7, is unable to encode an IRF9 protein that forms a functional ISGF3
transcription factor, while R292C and R292Q are hypomorphic and Q127H is neutral. To
confirm these data, we also performed electrophoretic mobility shift assays (EMSAs) on
P’s cells following IFN-α2b stimulation and were not able to visualize ISRE-binding of the
ISGF3 complex, although her cells were able to form GAF complexes and bind GAS
elements under the same conditions (Fig. 2.2G). Although we cannot exclude the
possibility that the splicing defect is leaky in untested cells where IRF9 D331N is
expressed, resulting in a severe but incomplete IRF9 deficiency, the most parsimonious
conclusion is that the patient is homozygous for a null IRF9 allele.

IRF9 deficiency impairs induction of ISGs
Because P’s cells were unable to form a functional ISGF3 complex, we further
hypothesized that her cells would display a severe impairment in ISG upregulation
following IFN stimulation. Unlike cells from healthy controls, stimulation of P’s SV40-F
and B-LCL cells with type I IFN of did not substantially induce MX1, IFIT1, or OAS1 gene
products as assessed by qRT-PCR at the transcriptional level and WB at the protein level
(Figs. 2.3A-D). Importantly, stable transfection of P’s SV40-F cells with a plasmid
encoding WT IRF9 was able to rescue the impaired induction of ISGs (Fig. 2.3E).
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Consistent with this, U2A cells stably transfected with WT IRF9 induced transcription of
classic ISGs normally, while cells transfected with IRF9-Δex7 were not able to do so (Fig.
2.3F). To verify the health of these cells and confirm that their defective response to type
I IFN was specific to that pathway, rather than a global defect in cytokine signaling, CXCL9
expression following stimulation with type II IFN was used throughout these qRT-PCR
experiments as a positive control. Type I IFN signaling induces a substantially broader
transcriptional response than upregulating the few genes tested above; in many cell types,
potentially hundreds of genes display altered expression levels111. We therefore performed
mRNA-sequencing (mRNA-seq) analysis of P’s B-LCL cells and primary fibroblasts
following in vitro stimulation with IFN-α2b in order to more fully characterize the
transcriptional responses of P’s cells to type I IFN. P’s B-LCL cells (Figs. 2.4B, D-G) and
primary fibroblasts (Figs. 2.4A, C, E-G) demonstrated an inability to regulate a broad array
of genes there were not limited to ISGs, but also included negatively regulated transcripts.
Importantly, the transcriptional response type I IFN in P's cells was not completely
abolished. Indeed, from all transcripts detected in P’s cells, 118 transcripts from her BLCLs and 267 transcripts from her primary fibroblasts passed our filter criteria for being
IFN-α2b-regulated and were also found to be regulated by IFN in the Interferome database
v2.01 (Figs 2.4C & D). Interestingly, the extent of ISG induction differed between P’s cells
and those of healthy controls, even when considering only those ISGs induced in P’s cells.
For instance, many of the up-regulated ISGs were significantly less induced in P’s cells
than those same ISGs were in healthy control cells, although a small subset of ISGs was
actually induced at higher levels in IRF9 deficient cells (Figs. 2.4E & F). To further dissect
the ISG network and its dysregulation in P's B-LCL cells, we next identified a subset of 84
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transcripts that were consistently strongly induced (> 5-fold linear scale) following IFNα2b stimulation of cells from healthy controls. Of these transcripts, only 37 were found to
be induced at any level (>1.5 fold) in her B-LCLs, while 47 were not induced. These
transcripts were then queried for ISGs in the Interferome v2.01 database, again using a 1.5fold cut-off to differentiate between IFN-responsive and non-responsive genes. Of these
37 responsive and 47 non-responsive transcripts in P's cells, 24 and 39 transcripts,
respectively, were identified as ISGs in the Interferome v2.01 database. These transcripts
were then used in an ISG response network analysis using GeneMANIA
(https://genemania.org) to predict which cellular functions may be disrupted by the lack of
ISG induction in P’s cells (Fig. 2.4G). Notably, genes encoding IFIT family proteins,
ISG15, and components of the ISGylation system such as USP18 and HERC5, were among
those ISGs not induced in P’s cells. Conversely, a number of ISGs, such as DDX58, those
for Guanylate-Binding Proteins (GBP1, GBP4, and GBP5), ISG20 and STAT2 were
induced by IFN-α2b in P's cells. Although most of these ISGs were not induced to a
comparable level in P’s cells as in healthy controls, these data are consistent with the
presence of ISGF3-independent transcription factors such as phosphorylated STAT1
homodimers downstream of the IFN receptor. Collectively, our studies indicate that P’s
cells are able to form functional GAF complexes and induce a small subset of ISGs, but
lack functional ISGF3 complexes due to expression a loss-of-function IRF9 allele that
severely narrows the transcriptional responses to type I IFN in multiple cell types.
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The patient’s fibroblast-intrinsic type I IFN immunity to viruses is impaired
Next, we assessed the impact of IRF9 deficiency on cell-intrinsic, nonhematopoietic immunity by infecting P’s SV40-F cells with either IAV or vesicular
stomatitis virus (VSV). At 48 hours post-infection (hpi), we observed an approximately
10-fold difference in IAV titer between P’s cells and those from healthy controls or P’s
heterozygous mother (Fig. 2.5A). We then considered whether the residual type I IFN
signaling enabled by the ISGF3-independent mechanisms could inhibit viral replication
following pretreatment with exogenous IFN. Pre-treatment with IFN-α2b substantially
reduced viral replication in healthy control cells but did not diminish replication in P’s
cells, which produced roughly 100-fold higher IAV titers than cells with intact type I and
III IFN signaling pathways (Fig. 2.5A). Consistent with these data, we also found that P’s
SV40-F cells were substantially more susceptible to VSV at 12 hpi in the absence of pretreatment with type I IFN. Pre-treatment with IFN-α2b was also unable to rescue this
phenotype, as P’s cells demonstrated a roughly 1,000-fold elevation in viral titer compared
with healthy controls at all time points beyond 8 hours (Fig. 2.5B). To determine whether
or not these defects in IAV and VSV immunity were IRF9-dependent, we then stably
transfected P’s SV40-F cells with various IRF9 alleles, or an empty vector (EV), and
analyzed the ability of the transfected cells to control VSV and IAV infection (Figs 2.5C
& D). Importantly, expression of WT IRF9 was able to rescue the inability of P’s cells to
control of infection with either pathogen, as did expression of the Q127H variant,
suggesting that this allele may not be deleterious in the context of type I IFN signaling and
anti-viral immunity, consistent with the lack of severe viral infections experienced by the
individual carrying this mutation in homozygosity. Conversely, expression of K81R or
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IRF9-Δex7 was unable to rescue the elevated viral replication phenotypes of P’s SV40-F
cells. Introduction of the R292Q or R292C alleles resulted in an intermediate phenotype,
as these cells were somewhat able to control infection with VSV or IAV, though not at the
level of the WT IRF9 allele. This, then, suggests that a partial form of IRF9 deficiency may
have contributed to the viral infections of the HOIL1 deficient patient102. To test whether
IRF9 deficiency resulted in impaired cell-intrinsic anti-viral immunity to other human
pathogens, we next infected patient and controls SV40-F cells with GFP-expressing PIV
and RSV (Figs. 2.5E-H). Consistent with our results in IAV and VSV infections, we
observed a larger proportion of infected cells, and greater replication of viruses in P’s cells,
as assessed by GFP intensity, than in healthy controls at 48 hpi (Figs. 2.5E-H). Lastly, to
further demonstrate that IRF9 mediates susceptibility to viral infection in vitro, we
transfected primary dermal fibroblasts from healthy individuals with siRNAs targeting
IRF9, mitochondrial-antiviral signaling protein (MAVS), or a non-targeting siRNA
(siNeg) (Fig. 2.6A). Knockdown of either IRF9 or MAVS resulted in increased HRV viral
transcripts compared to cells transfected with siNeg (Fig. 2.6A). Similarly, knockdown of
IRF9 or MAVS increased the number of infected cells and relative number of viral
transcripts following infection with either RSV or PIV (Figs. 6C-E). These data therefore
suggest that IRF9 is nonredundant for immunity to positive-sense RNA viruses in addition
to the negative-sense viruses already tested. Collectively, these studies indicate that IRF9
deficiency leads to a broad defect in cell-intrinsic immunity to viruses in vitro, and that
inherited IRF9 deficiency underlies P’s impaired immunity to influenza infection and her
subsequent hospitalization for ARDS in natura.
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Discussion
This study describes autosomal recessive, complete IRF9 deficiency in a child who
suffered a life-threatening influenza infection. Our data establish a causal relationship
between IRF9 deficiency and this patient’s severe pulmonary influenza97. Thus, IRF9
deficiency constitutes the fourth genetic etiology for life-threatening influenza
pneumonitis, after AR IRF7 deficiency, GATA2 haploinsufficiency, and AD TLR3
deficiency2,17,68. Whereas IRF7 deficiency disrupts the amplification of antiviral IFNs,
IRF9 deficiency results in an inability of all cell types to respond effectively to type I, and
likely type III, IFNs41. The obvious mechanistic connection between IRF7 and IRF9
deficiency suggests that the type I IFN responses driven by IRF7 amplification and
mediated by IRF9 signaling are essential for defense against influenza virus in humans.
Counter to this hypothesis, however, patients with other defects in type I IFN signaling
pathway, including deficiencies in STAT1, STAT2, JAK1, TYK2, or IFNAR2 are not
known to have experienced severe influenza infections49–52,73–75. A number of alternative
hypotheses could explain this discrepancy: (i) patients with these defects may have died
from other severe infections prior to exposure to influenza virus, (ii) influenza virus can be
controlled independently of these signaling proteins, or, similarly, (iii) at least some type I
IFNs can signal without these proteins, or, (iv) some of the defects previously described
are partial, as opposed to complete, due to the hypomorphic nature of some mutant alleles
49,51,112,113

. Our data suggest that IRF9 and IRF7 regulate transcription of a key subset of

ISGs that specifically mediate immunity to influenza virus. A clearer picture of the
contributions of type I and III IFN signaling to human protective immunity against
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influenza virus will emerge as more inborn errors of immunity are discovered and as more
patients with previously described defects are diagnosed.
Subsequent to the completion of this study, a second patient with inherited IRF9
deficiency was identified with a broader clinical phenotype, including ICU admission
following vaccination against varicella zoster virus (VZV), as well as enterovirus, Zika
virus, and dengue virus infections, and an IAV-induced pneumonia which required
hospitalization but not admission to the ICU114. In contrast with MDA5 deficient patient
who was prone to severe, recurrent HRV and RSV infections, as well as other viral
infections of the respiratory tract not including influenza, P was not admitted to the ICU
following infection with RSV or HRV, both of which were confirmed by serology and
VirScan45,69,70. Similarly, the second IRF9 deficient patient was also not admitted to the
ICU following RSV or HRV infections114. Together, these data suggest that IRF9
deficiency and MDA5-deficiency may result in largely non-overlapping viral
susceptibilities, with MDA5 deficiency leading to severe respiratory tract infections
excluding influenza, while IRF9 deficiency results in especially profound susceptibility to
influenza virus, and possibly to non-respiratory viruses such as enterovirus and some
flaviviruses. MDA5 and IRF9 may therefore be necessary for control of different sets of
respiratory viruses. Intriguingly, IRF7 deficiency results in a narrow infectious phenotype,
as the only reported case in humans was uniquely susceptible to influenza infection at last
follow-up, aged 9 years, and has not received prophylaxis against further viral infections
other than an annual influenza vaccination41. In comparison with IRF7 deficiency, then,
IRF9 deficiency may result in a broader infectious phenotype not limited to infection with
influenza virus, but also including other viruses unrelated to the respiratory tract.
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Significantly, P’s clinical phenotype might have been even broader if the patient had not
been started on IVIgs at 2 years of age. Despite this, IRF9 deficiency is still clinically more
similar to IRF7 deficiency than it is to GATA2 deficiency. Indeed, all known patients with
GATA2 deficiency suffered from many other severe infections, including mycobacterial
infections, papilloma virus infections, blastomycosis, and repeated viral infections of the
respiratory tract62. Severe influenza was the presenting feature in only a single GATA2
deficient patient who thereafter displayed other phenotypes, infectious and otherwise64.
The broad infectious phenotypes seen in these patients are consistent with the
immunological phenotype of GATA2 deficiency, which is not restricted to a lack of IFNproducing pDCs but can include monoMAC syndrome-like monocytopenia with B and NK
cell lymphopenia, in addition to myelodysplastic syndromes78,115. Significantly, only a
single case of IRF7 deficiency has been reported thus far, and only two cases of IRF9
deficiency. Further studies are needed to more comprehensively define the viral
susceptibilities resulting from these deficiencies, to determine the extent to which IRF7and IRF9-dependent type I and III IFN immunity is redundant for protective immunity
against viral infections, and to suggest what other factors may compensate for deficiencies
in this pathway.
Considering other patients with defects in the type I or III IFN signaling pathways,
complications from MMR vaccination have been reported in patients with IFNAR2,
STAT1, or STAT2 bi-allelic mutations49–52,116. Although comparatively rare in STAT1
deficient individuals, a severe though incompletely characterized adverse was reported in
the only individual with AR complete STAT1-deficiency who was vaccinated against
MMR116. Furthermore, it is unclear whether the patients with STAT2 and IFNAR2
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deficiency have a complete or partial deficiency49–52. Interestingly, MMR vaccine
complications have not observed in patients with AR partial STAT1 deficiency, nor have
they been reported in patients with partial JAK1 or complete TYK2 deficiency who were
vaccinated73–75. These data suggest a possible divergence from mice, where STAT1 is
dispensable for protection against measles virus while STAT2 is not117,118. One possible
explanation for the discrepancy between mice and humans is that STAT2 and IRF9 mediate
a physiologically relevant branch(es) of the IFN signaling pathway(s) in mice
independently of STAT1, while some subset of these branches is relevant for measles virus
immunity in humans in a STAT1-dependent manner. Previous studies have described
STAT2-IRF9 complexes in both mice and humans, although it is unclear if they are
transcriptionally active enough to drive the cellular changes required for defense against
viral infection119,120. This hypothesis would be consistent with previous experiments in
mice demonstrating that the different components of the ISGF3 complex regulate distinct,
non-redundant subsets of ISGs in addition to a jointly-regulated core of genes121.
Alternatively, the different MMR phenotypes in patients with various inborn errors of type
I and/or III IFN immunity may simply reflect the impact of modifier genes in these
individuals, or of the environment itself, including the MMR inoculum. Ultimately, the
experiment of nature deciphered in this report reveals the non-redundant roles of human
IRF9 in the type I and/or III IFN signaling pathways for cell-intrinsic immunity against
influenza virus and likely also the MMR vaccine.
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Figure 2.1. A private IRF9 variant alters mRNA splicing in a child with severe
influenza pneumonitis. (A) Pedigrees of the IRF9 deficient family. The double lines
connecting the parents indicate consanguinity. The proband is indicated by an arrow. Filled
shapes indicate affected individuals while open shapes identify unaffected individuals. (B)
Chromatograms demonstrating c.991G>A mutation in patient PBMC-derived DNA (red
arrow). (C) Population genetics of homozygous coding missense and predicted loss of
function IRF9 mutations taken from GnomAD and in-house cohorts. The patient’s variant
is private and shown in red, while two other variants, shown in blue, were also identified
in our cohort. (CADD: Combined Annotation Dependent Depletion; MAF: Minor allele
frequency; MSC: Mutation Significance Cutoff) (D) Schematic illustration of the IRF9
gene. The exons are numbered 1-9 and regions corresponding to functionally significant
domains are colored brown (for the DNA-binding domain, DBD), grey (nuclear
localization sequence, NLS), or purple (IRF-association domain, IAD). Patient mutation
indicated in red, other mutations indicated in blue. (E) IRF9 transcripts (left panel) and
relative frequencies (right panel) produced during exon trapping in U2A cells. The results
are representative of two independent experiments. (F) cDNA sequencing to detect the
splicing of IRF9 mRNA from F-SV40 cells. Numbers of total and abnormal clones
sequenced are indicated. Results representative of two experiments.
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Figure 2.2. Impact of IRF9 Dex7 on IFN receptor-proximal signaling. (A) qRT-PCR
measuring of IRF9 mRNA levels in PBMCs from the patient, her mother, and a healthy
control with two probes; one probe spanning intron 7, and a second probe spanning intron
1. (B) Upper panel: Western blot of endogenous IRF9 in patient F-SV40 cells; GAPDH
was used as a loading control. Lower panel: STAT and phospho-STAT (pSTAT) levels
were also assessed following stimulation with 1000 U/ml of either IFN–α2b or –γ for 0.5
hours on F-SV40 cells from two healthy controls (C1 and C2), the IRF9-deficient patient
(IRF9 -/-), her mother (IRF9 +/-), a STAT1-deficient patient (STAT1 -/-), a STAT2deficient patient (STAT2 -/-), an IFNGR2-deficient patient (IFNGR2 -/-), and an IRF7deficient patient (IRF7 -/-). Representative results of three independent experiments are
shown. (C) Western Blot of IRF9 in IRF9-deficient U2A cells stably transfected with
indicated variants (green: variants reported to be loss of function in in vitro assays, blue:
variants found in-house, red: patient). GAPDH was used as loading control. (D) Western
Blot of IRF9 in patient F-SV40 cells stably transfected with indicated variants. GAPDH
was used as loading control. (E) Western blot analysis of IRF9 localization in F-SV40 cells
from two healthy controls (C1 and C2), the IRF9-deficient patient (IRF9 -/-), her mother
(IRF9 +/-), a STAT1-deficient patient (STAT1 -/-), a STAT2-deficient patient (STAT2 -/), an IFNGR2-deficient patient (IFNGR2 -/-), and an IRF7-deficient patient (IRF7 -/-).
GAPDH and LaminA/C were used as loading controls. Representative results of three
independent experiments are shown. (F) Reporter assays of ISRE or GAS-dependent firefly
luciferase tested in U2A cells stimulated with 1000 U/ml of either IFN -α2b or -γ for 16
hours after being stably transfected with indicated variants (green: variants reported to be
loss of function in in vitro assays, blue: variants found in-house, red: patient). The specific
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response to IFN stimulation was calculated by the ratio of firefly luciferase reporter gene
activity to constitutively expressed renilla luciferase activity (RLU, relative luciferase
ratio). Representative results of three independent experiments are shown. (G) EMSA
analysis of ISRE and GAS binding by IFN stimulated B-LCLs from three healthy controls
(C1, C2, and C3), the IRF9-deficient patient (IRF9 -/-), her mother (IRF9 +/-), a STAT1deficient patient (STAT1 -/-), a STAT2-deficient patient (STAT2 -/-), and an IRF7deficient patient (IRF7 -/-). Representative results of two independent experiments are
shown.
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Figure 2.3. Impaired ISG induction in IRF9-deficient cells. (A) Transcription levels of
MX1, IFIT1, IFIT3, and CXCL9 assessed by qRT-PCR on F-SV40 cells treated with
1000U/ml of either IFN –α2b, -b, or –γ for 2 hours. Cells were from three healthy controls
(C1, C2, and C3), an IRF9-deficient patient (IRF9 -/-), her mother (IRF9 +/-), STAT1deficient (STAT1 -/-), STAT2-deficient (STAT2 -/-), IRF7-deficient (IRF7 -/-), and
IFNGR1-deficient (IFNGR1 -/-) patients. Representative results of three independent
experiments are shown. (B and C) Western blot of MX1 and IFIT3 on F-SV40 (B) or BLCL (C) cells treated with 1000U/ml of IFN–α2b for various time points. GAPDH was
used as a loading control. (D) Transcription levels of MX1, IFIT1, IFIT3, and CXCL9
assessed by qRT-PCR of B-LCL (D) cells treated with 1000U/ml of either IFN –α2b, -b,
or –γ for 2 hours. Cells were from three healthy controls (T1, T2, and T3), an IRF9deficient patient (IRF9 -/-), her mother (IRF9 +/-), STAT1-deficient (STAT1 -/-), STAT2deficient (STAT2 -/-), IRF7-deficient (IRF7 -/-), and IFNGR2-deficient (IFNGR2 -/-)
patients. Representative results three independent experiments are shown. (E)
Transcription levels of of MX1, IFIT1, and CXCL9 assessed by qRT-PCR in F-SV40 cells
from healthy control (C1), P’s mother (IRF9 +/-), and P (IRF9-/-) stably transfected with
luciferase as a control (luc) or indicated IRF9 variants (WT: wild type IRF9, green:
reported loss of function variants, blue: variants found in-house, red: patient variant). Cells
were stimulated with 1000 U/ml of either IFN -α2b, -b, -γ for 2 or 8 hours. Representative
results of two independent experiments are shown. (F) Similar to (E), qRT-PCR analysis
of MX1, IFIT1, and CXCL9 expression in parental HT1080 cells and U2A cells. Cells were
stimulated with 1000 U/ml of either IFN -α2b, -b, or -γ for 2 or 8 hours. Representative
results of three independent experiments are shown.
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Figure 2.4. Transcriptomic analysis of ISGs in IRF9-deficient cells. mRNA-seq
analysis of primary fibroblasts (A & C) and B-LCLs (B & D) from three healthy controls
(C1, C2, and C3), the IRF9-deficient patient (IRF9 -/-). Cells were treated with 1000U/ml
IFN –α2b for 2 hours. Heatmaps (A & B) show log2 FC values of all ISGs that were found
to be differentially regulated (>= 1.5 fold) in all three control subjects relative to
unstimulated cells. Bar graphs (C & D) quantify the number of ISGs that were differentially
regulated (>= 1.5 fold) compared to unstimulated cells in healthy controls or the IRF9
deficient patient. (E) Shown are Δ log2 fold change values of a subset of interferon
stimulated genes (ISGs) that were found to be induced ≥ 1.5 fold (linear scale) in B-LCL
cells (upper panels) or primary fibroblasts (lower panels) of the IRF9-deficient patient upon
in vitro stimulation with IFN-a. To select this subset of ISGs, the IFN-a2b-induced genes
in the healthy controls identified in the mRNA-Seq analysis were used. In the IRF9deficient patient, these genes were first passed through a filter by querying the gene
identifiers against the interferome database and by retaining genes that were responsive to
in vitro interferon stimulation. ISGs that failed to be induced at least 1.5 fold (linear scale)
in patient cells were excluded. The retained ISGs were stratified in three groups of less (Δ
< -0.585), similar (-0.585 < Δ < 0.585) and higher (Δ > 0.585) induced genes relative to
the average responses in the healthy control subjects. The number of genes in each group
are shown in brackets. *** denotes significant differences at p<0.0001 by the KruskalWallis test. (F) Log2 FC of induced ISGs in IRF9-deficient B-LCLs (upper panels) or
primary fibroblasts (lower panels) and their corresponding values in healthy donors. (G)
Network analysis of a subset of highly inducible (> 5 fold linear scale) ISGs among control
subjects' B-LCLs and their responsiveness in the IRF9-deficient patient. Biological
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pathway and physical interactions are depicted as blue and red lines, respectively. 1.5 FC
was used as cut-off to distinguish responsive (red circle) and non-responsive (blue circle)
ISGs. The highly inducible ISGs that were used for query are shaded in yellow.
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Figure 2.5. Crippled control of IAV and other viral infections in IRF9-deficient cells.
(A) IAV titers in F-SV40 unstimulated (left) or pre-treated (right) with 1000U/ml IFN-α2b
for 16 hours, followed by infection with (A/H1N1/CA/2009) IAV at MOI = 1. Means ±
SD (n = 3) are shown. Cells from three healthy controls were included (C1, C2, and C3),
as well as those from the IRF9-deficient patient (IRF9 -/-), her mother (IRF9 +/-), and
STAT1-deficient (STAT1 -/-), STAT2-deficient (STAT2 -/-), and IRF7-deficient (IRF7 /-) patients. (B) VSV titers in F-SV40 cells unstimulated (left) or pre-treated (right) with
1000U/ml IFN-α2b for 16 hours, followed by infection with VSV at MOI = 3. Three
independent experiments (means ± SD) are shown. (C) IAV titers in stably transfected FSV40 cells unstimulated (left) or pre-treated (right) with 1000U/ml IFN-α2b for 16 hours,
followed by infection with IAV at MOI = 1. Cells were from a healthy control (C1), a
STAT1-deficient patient (STAT1-/-), P (IRF9-/-), and P’s cells stably transfected with
luciferase or wild type IRF9 (grey), variants reported to be loss-of-function in in vitro
assays (green), variants found in-house (blue), or the patient’s variant (red). Three
independent experiments (means ± SD) are shown. (D) VSV titers in stably transfected FSV40 cells unstimulated (left) or pre-treated (right) with 1000U/ml IFN-α2b for 16 hours,
followed by infection with VSV at MOI = 3. Three independent experiments (means ± SD)
are shown. (E) Percentage of RSV-infected (GFP+) F-SV40 cells at 24 and 48 hours postinfection. Cells from three healthy controls were included (C1, C4, and C5, black), as well
as those from the IRF9-deficient patient (IRF9 -/-, red), and cells from STAT1-deficient
(STAT1 -/-), STAT2-deficient (STAT2 -/-), and IRF7-deficient (IRF7 -/-) patients. Three
independent experiments (means ± SD) are shown. (F) Mean fluorescence intensity (MFI)
of RSV-infected (GFP+) F-SV40 cells at 24 and 48 hours post-infection. Three
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independent experiments (means ± SD) are shown. (G) Percentage of PIV-infected (GFP+)
F-SV40 cells at 24 and 48 hours post-infection. Three independent experiments (means ±
SD) are shown. (H) MFI of PIV-infected (GFP+) F-SV40 cells at 24 and 48 hours postinfection. Three independent experiments (means ± SD) are shown. MFI of GFP positive
cells in individual samples were normalized to the averaged MFI of the three healthy
controls at 24 hours post-infection in (F) and (H).
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Figure 2.6. IRF9 is required for optimal control of viral infections. (A) WB confirms
the efficiency of RNAi of IRF9 or MAVS in primary dermal fibroblasts. (B-F) Primary
human dermal fibroblasts previously transfected with the indicated siRNA (negative
control, IRF9, MAVS) were tested for control of HRV, RSV, and PIV. Cells were infected
with HRV-A16 at MOI of 10 (B), RSV at MOI of 0.5 (C & D), or PIV3 at MOI of 0.1 (E
& F). Relative HRV transcripts (B) were measured by qRT-PCR and values were
normalized to the siNeg control. % infected cells (C & E) and relative virus per infected
cell (D & F) were measured by flow cytometric analysis of GFP positive cells. MFI of GFP
positive cells in individual samples were normalized to negative control at 24 hours (D, F).
Shown are the mean ± SD of six (B-F) experiments. *, p < 0.05; **, p < 0.01, by KruskalWallis test.
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Figure 2.S1. VirScan analysis of specific anti-viral antibodies detected in patient sera.
Positive identification requires antibodies recognizing at least three epitopes specific to a
given virus. Positive cells are colored black, whereas negative cells are colored light grey.
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Figure 2.S2. IRF9 splicing in patients with c.991+119T>G and c.991+188C>A
mutations. cDNA sequencing was performed to detect the splicing of IRF9 mRNA in
patients heterozygous for mutations in a possible alternatively spliced transcript which
retains an additional exon between exons 7 and 8 of the canonical transcript. cDNAs were
generated from patient and control (CTL) F-SV40 cells. Numbers of total and abnormal
clones sequenced are indicated. Results are representative of two experiments.
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Figure 2.S3. Exon trapping scheme. Diagram of IRF9 mRNA in the region containing
exon 7 inserted into the pSPL3 exon trapping system with or without the c.991G>A
mutation indicated with a vertical red line. Exons are depicted as boxes while noncoding
sequences are lines. Primers used in cDNA sequencing are demonstrated, and the
nucleotide lengths of the features are shown in parenthesis. HIV-TAT sequences present
in the pSPL3 vector are colored grey and brown.
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Table 2.S1. Rare homozygous or possible compound heterozygous variants found by
exome sequencing of P. Genes listed in red are homozygous while those in black may be
compound heterozygous or may occur on the same allele. † indicates a gene containing a
stop-gain mutation, while ‡ indicates a gene that is predicted to be related to PIDs via a
connectome analysis100.
TGM6

APEX2‡

TMEM1

TOP2A‡

CHAMP2 CDH26

CBFA2T3‡ GCFC2

NBAS

DACT2†

NINL

BMP6‡

MAP3K15‡ ENTHD1†

NUMA1

UBTPF

SLC12A

GBGT1†

CXCL11

CCSER1

ABHD4

RP11

COG1

TPCN1

PLCB4

MAPT
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FAM189B

CATSPERD IRF9‡

BCAR3

XRN2‡

BRDT

Table 2.S2. Immunophenotyping of P’s lymphocytes. Clinical immunophenotyping
was performed on fresh PBMCs isolated from the patient at age 2. Standard values for a
child in this age range are given on the right, and atypical values are bolded.
Parameter

Patient values

Total lymphocytes (cells/µL)

4100

T lymphocytes
CD3+ %
CD3+
CD4+ %
CD4+
CD8+ %
CD8+
CD45RO+/CD4+ %
CD45RA+/CD4+ %
CD31+/CD4+%
CD31+/CD45RA/CD4+ %

57
2337
32
1312
18
738
36.5
63.5
58
48

B lymphocytes
CD21++CD24+/CD19+ %
CD27+ IgD+/CD19+ %
CD27- IgD+/CD19+ %
CD24++CD38++/CD19+ %
CD24++D38++CD27IgD+/CD19+ %
CD24-CD38++/CD19+ %
CD21-CD38-/100 lymphocytes
CD19+ %
CD19+
CD27+/CD19+ %
CD27+ IgD-/CD19+ %

Normal range for 2-5
years old

56 - 75
1400 - 3700
28 - 47
700 - 2200
16 - 30
490 - 1300
73 - 86
57 - 65

87
4
86
4
5

4.6 - 16.3
69.2 - 90.5

0.2
3
32
1312
10
6

7.6 - 28.2
319 - 1244
7 - 24.3
2.7 - 12.5

NK lymphocytes
CD16+CD56+ %
CD16+CD56+

9
369

4 - 17
130 - 720

Diverse T lymphocyte markers
CCR7-CD45RA+/CD8+ %
CCR7+CD45RA+/CD8+ %
CCR7-CD45RA-/CD8+ %
CCR7+CD45RA-/CD8+

13
52
29
6

16 - 28
52 - 68
11 - 20
3-4

49

Table 2.S3. Proliferation of P’s lymphocytes. Lymphocytes were isolated from P’s blood
and stimulated with the given antigens. Cell numbers were assessed on day 3 (PHA) or day
6 (all other stimuli).
Cell number (cpm/103)
1.6
67
1.1
71
59
2.5
2.5
5.5

Condition
Non stimulated (day 3)
PHA
Non stimulated (day 6)
Tuberculin
Candidin
Tetanus
Cytomegalovirus
Herpes simplex virus
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Chapter 3:
Inherited IFNAR1 deficiency as a genetic etiology for adverse reactions to MMR
and yellow fever virus live vaccines2

2

Chapter 3, and portions of the materials and methods, are edited from: Hernandez, N. et al. Inherited
IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live
vaccines. The Journal of Experimental Medicine jem.20182295 (2019). doi:10.1084/jem.20182295
This manuscript can currently be found at http://jem.rupress.org/content/early/2019/07/02/jem.20182295.
Author contributions are available in the acknowledgements section of this thesis, in addition to being more
fully elaborated in the manuscript itself.
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Introduction
There are currently eleven live attenuated viral (LAV) vaccines in use worldwide,
all of which have been shown or suspected to cause life-threatening disease in rare
individuals. To date, inborn errors of immunity have been shown to underlie severe disease
due to three LAV vaccines, in at least some patients. Patients with agammaglobulinemia
due to an inborn errors of T or B cells can develop vaccine-associated paralytic
poliomyelitis following administration of the live (oral) poliovirus vaccine120. Similarly,
patients with severe combined immunodeficiencies can develop life-threatening
dehydration following administration of the oral rotavirus vaccine123. Lastly, a lifethreatening vaccine-strain mumps infections has been reported in a single patient with
RAG1 deficiency and a lack of T and B cell adaptive immunity124. More recently, a number
of defects within genes that control cellular responses to type I and/or III IFNs, including
STAT1 and STAT2 (both of which mediate type I and III IFN signaling), and IFNAR2
(which mediates type I IFN signaling alone), have been described in patients with
disseminated measles infections following MMR vaccination49–51,116. Additional defects in
the type I IFN signaling pathway have also been associated with adverse reaction to the
MMR vaccine. One patient with a complete deficiency in IRF7, which controls the
amplification of type I and III IFNs, developed a self-limiting rash post vaccination. The
IRF9 deficient child described in Chapter 2, meanwhile, experienced a biliary perforation
of unknown etiology one week after MMR vaccination41,125. These defects are unable to
account for the majority of adverse reactions to the MMR vaccine. Genetic causes have not
been established for severe adverse reactions to live vaccines for rubella virus, yellow fever
virus (YFV), influenza virus, VZV, vaccinia virus, or hepatitis A virus. We studied two
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otherwise healthy patients who developed disseminated, life-threatening disease following
LAV vaccination: a 9-year-old Iranian boy who developed disease following MMR
vaccination at 1 year and whose younger sister died at 1 year following MMR vaccination,
and a 14-year-old Brazilian girl who developed disease following YF vaccination at age
12.

Results
Two unrelated patients with adverse reactions to LAV vaccines
We studied two unrelated patients whose pedigrees are shown in Figure 3.1A, and
for whom full case reports are available in the materials and methods section. Patient 1
(P1) was born to consanguineous parents in Iran and had no notable past medical history.
He presented at one year of age with disseminated vaccine-strain measles (Fig. 3.1A),
roughly ten days after inoculation with the MMR vaccine. The patient developed a
generalized exanthem, fever and neurological symptoms consistent with encephalitis.
Analysis of

P1’s cerebrospinal

fluid (CSF)

demonstrated

leukocytosis (350

lymphocytes/uL, 2 neutrophils/uL), and PCR for measles was positive both in blood and
CSF. A computed tomography (CT) of P1’s brain evidenced mild cerebral edema. P1
recovered and is now 9 years old. He remains in good health, without experiencing
subsequent life-threatening infections. Additionally, P1 had a younger sibling who died
four weeks after routine MMR vaccination at age 1 year, although no material from this
child was available for genetic analysis. Finally, P1’s mother electively terminated a third
pregnancy following prenatal genetic identification of the same homozygous variant in
IFNAR1 that was present in P1. Patient 2 (P2) is a 14 year-old Brazilian girl born to non-
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consanguineous parents (Fig. 3.1A). P2 had no significant medical history until age 12,
when she presented with fever, hypotension, vomiting, and lethargy seven days following
YF vaccination. She became obtunded, developed severe renal and hepatic dysfunction,
and ultimately required intubation and mechanical ventilation. YFV RNA was detected in
the patient’s blood by PCR at this time, and a CT scan of her chest demonstrated pleural
effusions and atelectasis (Fig. 3.1B). Sequencing of the YFV recovered from the patient
confirmed that the vaccine-strain YFV, rather than an environmental strain, was the cause
of her illness (Fig. 3.S1)126. On this basis, a diagnosis of yellow fever vaccine-associated
viscerotropic disease (YEL-AVD) was made. She does not belong to any known risk
groups for YEL-AVD, which include the elderly, individuals with autoimmune diseases
such as lupus, and those who have undergone thymectomy for thymoma treatment127. Two
years after recovery, P2 remains healthy. Especially notable in this context, P2 received
two MMR vaccinations at 12 and 16 months of age, as well as the oral poliovirus and BCG
vaccines, without incident. Serological analysis detected neutralizing antibodies against
YFV in levels associated with seroprotection, and seropositivity to measles, rubella,
diphtheria, and tetanus antigens, indicating that her adaptive immune responses were intact.
Bi-allelic private nonsense or splicing IFNAR1 variations in the patients
We hypothesized that inborn errors of immunity may underlie these patients’
vaccine-related diseases. To test this, we first performed WES analysis on both patients.
Principal component analysis confirmed the ethnicities of the two families, and the
percentage of homozygosity in P1 and P2’s exomes (2.9% and 0.25%, respectively) was
consistent with P1 being born to consanguineous parents96. We proceed to analyze each
patients’ exome for the presence of copy number variations and single nucleotide
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variations. We first filtered out common variants (those with a MAF >0.01), as well as
noncoding and synonymous single nucleotide variations, excepting those that were
predicted to disrupt essential splice sites. We then removed variants that were predicted to
be benign (that is, those with a CADD score below the MSC), and variants that occur in
frequently damaged genes (those with a GDI >13.84)98,99,101. Lastly, we investigated a
model of AR inheritance and discarded all variants that were not found either in the
homozygous or compound heterozygous states in these individuals. In P1, 48 variants in
39 genes passed our filtering criteria, including a private homozygous mutation in IFNAR1,
c.674-2A>G (Table 3.S1). In P2, we identified two variants in IFNAR1,
c.783G>A;p.W261X and c.674-1G>A, in addition to 9 other variants in 5 genes passing
our filtering criteria (Table 3.S1) (Fig. 3.1C). The IFNAR1 gene encodes one subunit of the
heterodimeric receptor for the type I IFNs, and is therefore critical for functional type I
IFN signaling128,129. The three IFNAR1 mutations are predicted to be deleterious either by
disrupting the same essential splice site, (c.674-2A>G and c.674-1G>A, in P1 and P2,
respectively), or by creating a premature stop codon (p.W261X in P2). All three IFNAR1
variants were absent from online databases including 1000 Genomes, Bravo, and gnomAD
(Fig. 3.1D). The three variants were confirmed by Sanger sequencing of the patients and
their relatives, which also verified that the variants present in P2 occurred on different
alleles, consistent with the hypothesis of an AR pattern of inheritance (Figs. 3.1A and
3.S2A). Seven nonsynonymous IFNAR1 variants were found in homozygosity in gnomAD,
none of which were predicted to affect splicing or introduce a premature stop codon (Figure
1D). The lack of known loss-of-function mutations in IFNAR1, combined with the rarity
of nonsynonymous mutations, indicates that mutations that may affect IFNAR1 function
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are selected against. Altogether, these findings suggested that the two patients suffered
from AR IFNAR1, a novel and rare inborn error of immunity.

The three mutant IFNAR1 alleles encode truncated proteins
We then set out to investigate the consequences of the mutations in the patients’
IFNAR1 alleles on transcription and translation of their gene products. In particular, we
hypothesized that c.674-1G>A and c.674-2A>G mutations would lead aberrantly spliced
transcripts, as they occur at the essential splice acceptor site of exon 6 (Fig. 3.1C). To test
this, we amplified IFNAR1 cDNAs generated from the patients’ or a healthy control’s
SV40-F cells (Figs. 3.2A, 3.S2B & C) and Sanger sequenced individual cDNA clones.
Significantly, all IFNAR1 transcripts present in healthy control cells contained normal
splicing at exon 5-6 and 6-7 junctions, whereas three alternative splice products were
observed in P1 and P2. In both P1 and P2, approximately 60% of transcripts lacked exon
6, while 30-40% of transcripts lacked the first 24 base pairs of exon 6. Deletion of the
entirety of exon 6 introduces a frameshift and a premature stop at aa 228 (p.V225AfsX228),
while deletion of the first 24 base pairs in exon 6 results in an in-frame deletion of aa 225
to 232 (p.V225_P232del). Additionally, a trace amount of transcripts utilized an alternative
pair of splice donor and acceptor sites within intron 5 to introduce a 56 bp segment into the
IFNAR1 transcript (Fig. 3.S2B). These transcripts were visible by DNA electrophoresis,
but were not initially detected by cDNA sequencing. The introduction of this sequence
would result in the introduction of a stop codon after three aa (p.T224_V225insESTX). For
simplicity, we will refer to these mutations as V225fs, V225_P232del, and T224ins,
respectively. In addition to the previously described transcripts, about 10% of transcripts
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isolated from P2’s cells were found to contain normal splicing at the exon 5-6 and 6-7
junctions. In all such cases, the transcripts also contained the nonsense mutation c.783G>A,
p.W261X (subsequently W261X). Western blot analysis of HEK293T cells overexpressing
the 4 patient-derived transcripts and WT IFNAR1 transcripts showed that all 4 proteins can
be expressed, albeit with correspondingly lower molecular weights than the WT protein
(Fig. 3.2B). These findings suggested that any proteins encoded by the three mutant
IFNAR1 alleles are unlikely to be functional.

The patients’ IFNAR1 alleles abrogate IFNAR1 expression and signaling
We then hypothesized that the patients’ IFNAR1 alleles may impact IFNAR1
mRNA or protein expression and function. To test this, we first performed qRT-PCR on
patients’ cells, detecting a significant reduction of IFNAR1 mRNA when compared with
healthy controls, consistent with nonsense-mediated decay of some transcripts (Fig.
3.S2D). To confirm if this decrease in mRNA level would be reflected in the level of
IFNAR1 protein in their cells, we then analyzed the patients’ cells by both western blotting
and flow cytometry, utilizing distinct monoclonal antibodies for each technique (Figs.
3.2C, 3.2D, 3.2F, and 3.S3A). Significantly, IFNAR1 expression was not detectable by
either method in patients’ SV40-F and B-LCL cells when compared with healthy controls
or patients with other defects in the type I IFN signaling pathway, such as IRF7 -/-, STAT1
-/-, STAT2 -/-, and IRF9 -/- patients (Figs. 3.2C, 3.2D, 3.2F, and 3.S3A). Consistent with
earlier studies on TYK2 deficient cells, we found IFNAR1 expression to be highly
diminished in the absence of TYK2, though not completely abolished130. To determine if
IFNAR1 was necessary for the stability of its co-receptor, or vice-versa, we also examined
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IFNAR2 expression levels in all cell lines (Figs 3.S3B, 3.S3D). Both IFNAR1 and IFNAR2
were normally expressed in the absence of the other, consistent with current models of
ligand binding which predict that IFNAR1 binds to an IFN-IFNAR2 complex to initiate
signaling33. Although IFNAR1 expression was not detectable in either fibroblastic or
lymphoid cell lines derived from the patients, we cannot exclude the possibility that
IFNAR1 may be properly expressed in other cell types.
To establish the consequences of IFNAR1 deficiency on type I IFN signaling, we
next assessed phosphorylation of STAT1 and STAT2 in the patients’ SV40-F cells
following stimulation with IFN-a2b (Fig. 3.2E). No phosphorylation of STAT1 or STAT2
could be observed in the patients’ cells under these conditions, unlike healthy control cells.
Importantly, STAT1 was normally phosphorylated following IFN-γ stimulation, in P1 and
P2’s cells, indicating that the defective phosphorylation observed upon type I IFN
stimulation was not due to any global issue impacting JAK-STAT signaling. Consistent
with these data, downstream consequences of type I IFN signaling were also affected.
Classic ISGs such as MX1 and IFIT1 were upregulated in healthy control SV40-F cells in
response to IFN-α2b and IFN-b, but no such upregulation was observed in P1 or P2’s cells.
Interestingly, CXCL9 induction in patients’ cells in response to IFN-γ stimulation was
intact, and actually elevated to a level above that of healthy controls (Fig. 3.2G). Previous
reports in mice had indicated that the IFNAR1 receptor provides an essential scaffolding
function for the type II IFN receptor, and that type II IFN signaling may be reduced in the
absence of IFNAR1131. Our data do not support the existence of a similar mechanism in
humans. The qRT-PCR experiments described here indicated that the patients’ cells have
significant defects in type I IFN signaling that lead to impairment of MX1 and IFIT1
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induction comparable to the impairment observed in other patients with deficiencies in this
pathway, including STAT1, STAT2, IRF9, and IFNAR2 deficiencies. We therefore
conclude that the absence of responses to IFN-a2b and -b in the patients’ fibroblasts is
consistent with IFNAR1 deficiency.

Impaired antiviral immunity in the patients’ fibroblasts
Next, to assess if the defect in type I IFN signaling in the patients’ cells affected
their ability to control viral infections in vitro, we inoculated patient and healthy control
SV40-F cells with VSV following pretreatment of the cells with type I IFN or not (Fig.
3.3A). VSV is exquisitely sensitive to type I IFN and is commonly used to assess the
competency of this pathway during infection132. Healthy control cells that were pretreated
with IFN-a2b were able to control VSV replication by 24 hpi, while replication was not
suppressed in the patients’ cells, nor in cells from IFNAR2, STAT1, STAT2, and IRF9
deficient patients (Fig. 3.3A). We then tested whether a similar defect in control of viral
replication occurred following infection with YFV-17D, a vaccine strain of the yellow
fever virus highly similar to the one which caused P2’s infection (Fig. 3.3B). Both patients’
cells displayed an inability to control YFV-17D replication following pre-treatment with
IFN-b, when compared with cells from healthy controls. Interestingly, IRF7 deficient cells
were able to control YFV-17D replication to the same degree as healthy controls, in the
presence or absence of exogenous IFN-b, while STAT1, STAT2, IRF9, and IFNAR2
deficient cells were unable to control infection in either condition (Fig. 3.3B). This may
suggest that IRF7 deficient cells can induce expression of at least some type I IFNs in
response to YFV-17D.

To test this, we quantified the production of IFN-b, the
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predominant type I IFN produced by these fibroblasts, during the course of viral infection
(Fig. 3.S3G). Significantly, P1 and P2’s SV40-F cells were able to produce elevated
amount of IFN-b following infection with YFV-17D when compared with healthy controls,
confirming that the defective antiviral immunity was a consequence of abolished IFN
responses rather than due to diminished IFN production in the patients’ cells (Fig. 3.S3G).
Similarly, IFN-b expression in the IRF7 deficient cells was normal, consistent with earlier
reports that IFN-b production may not require IFNAR1- or IRF7-dependent
amplification133. These data strongly suggest that a lack of type I IFN signaling underlies
the patients’ cell-intrinsic immune defects in vitro.
We next hypothesized that the patients’ cellular phenotypes may be caused by the
lack of full-length IFNAR1, and tested this by transducing the patients’ fibroblasts with
WT IFNAR1, IFNAR2, or an empty vector (EV). Significantly, IFNAR1 expression levels
were only rescued in cells that had been transduced with WT IFNAR1 (Figs. 3.S3C and
3.S3E). Consistent with our hypothesis, only transduction of WT IFNAR1 restored the
patients’ responses to type I IFN, as assessed by induction of MX1 and IFIT1 following
stimulation with IFN-α2b or -b (Fig. 3.3C). Similarly, only transduction with WT IFNAR2
could rescue the type I IFN signaling defect in cells deficient in IFNAR2, confirming the
non-redundancy of these proteins. Importantly, patient cells transduced with WT IFNAR1
were able to better control viral replication than cells transduced with IFNAR2 or an EV,
indicating that the patients’ cellular defect in innate immunity is, at least partially, a product
of IFNAR1 deficiency (Figs. 3.3D, 3.3E, 3.S3F, and 3.S3H). We hypothesized, as well,
that IFNAR1 deficiency in P1 and P2’s cells may result in a broader cellular susceptibility
than might be expected from their clinical histories, similar to the IRF9 deficient patient
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described in Chapter 2. To test this, we infected patients’ cells with IAV
(A/CA/07/2009/H1N1 strain) and HSV-1, two viruses the patients had been exposed to
without developing severe disease (Figs. 3.S4A-F). Consistent with previous viral
challenges, both HSV-1 (Figs. 3.S4A-D) and IAV (Figs. 3.S4E & F) replicated to higher
titers in the patients’ SV40-F cells than in cells from healthy controls. We additionally
questioned whether the patients’ defects in IFNAR1 signaling might result in susceptibility
to other flaviviruses, including non-attenuated viruses which they may not have
encountered. To test this, we inoculated the patients’ SV40-F cells with either YFV-Asibi,
the WT YFV strain from which YFV-17D was developed, or dengue virus and monitored
viral titer (Figs. 3.S4G-J). In agreement with all other viruses tested, both patients displayed
an inability to control YFV-Asibi or dengue virus replication that could not be rescued by
pretreatment with exogenous IFN-b when compared to cells from a healthy control (Figs.
3.S4G-J). It is also likely significant that all defects in the type I IFN signaling pathway
result in an extremely similar virological phenotype in vitro, though not, apparently, in
natura. Collectively, these data establish that AR IFNAR1 deficiency results in a broad
defect in fibroblast-intrinsic immunity in vitro and underlies measles vaccine disease in P1
(and by inference in his deceased sister), as well as YEL-AVD in P2.

Discussion
This work describes AR IFNAR1 deficiency in two unrelated families suffering
from severe, vaccine-related diseases. Significantly, AR IFNAR2, STAT1, and STAT2
deficiencies have also been shown to underlie life-threatening complications following
MMR vaccination (Table 3.1), while IRF7 and IRF9 deficiency may lead to a poorly
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characterized, seemingly less severe susceptibility to measles vaccine disease41,49–
52,114,116,125

. Patients deficient in JAK1 or TYK2 have not been reported to experience

disease following MMR vaccination, which may be a consequence of the impaired but not
abolished responses to type I IFNs in these cells73–75,134. Altogether, these data suggest that
control of vaccine-strain measles virus may be mediated by a set of genes jointly regulated
by human IFNAR1, IFNAR2, STAT1, and STAT2, and perhaps by IRF7 and IRF9117,118.
It is notable that IFNAR1 and IFNAR2 deficiencies both result in measles virus vaccine
related-disease while deficiency in IL-10RB, a subunit of the type III IFN receptor, has not
been reported to produce this phenotype71,135–137. Consistent with these studies, the high
incidence of measles virus vaccine-related disease in patients with abolished type I IFN
signaling suggests that this pathway may be more critical for defense against the vaccinestrain virus than type III IFN signaling. Taken together, these studies therefore identify a
nidus of susceptibility to severe MMR disease in the type I IFN signaling pathway, but
they do not wholly untangle the mechanism of this susceptibility. Additional consideration
of the precise transcriptional consequences of various defects within this pathway may
provide insight into this question.
Our data also provide the first genetic explanation for YEL-AVD, demonstrating
that AR IFNAR1 deficiency may underlie this rare condition127. Although the YF vaccine
was among the first dozen vaccines developed, YFV remains a global health threat138.
Given declining rates in YF vaccination and growing concerns over vaccine safety, validity
aside, it is increasingly important to understand the pathogenesis of adverse reactions to
LAV vaccines. Furthermore, the study of YFV and its vaccine is of interest to studies of
other flaviviruses, and may have implications on the development of vaccines or treatments
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for emerging pathogens such as Zika virus. Following this reasoning, the uncertainty
regarding the cause(s) of YEL-AVD has accelerated attempts to develop an inactivated
alternative vaccine139–141. Concurrently, vaccines against dengue virus and Japanese
encephalitis virus, constructed from chimeric YF viruses in which specific prM-E
sequences are introduced into the YF vaccine virus backbone, are the basis of ongoing
clinical trials with controversial results142–144. A better understanding of the pathogenesis
of YFV infections, both environmental and vaccine-related, is therefore obviously critical
to the successful development of safer vaccines related to YFV-17D. Importantly, studies
aiming to detect YFV-17D viremia in healthy vaccine recipients typically found virus
within 5-7 days following vaccination, and no deficiency of adaptive immunity has been
found in individuals with YEL-AVD145–147. Furthermore, the YFV-17D virus has been
found to promote the induction of critical type I IFN mediators such as STAT1 and IRF7
in humans, and recent work in mice has shown that intact type I IFN signaling is critical
for control of YFV-17D148–151. Consistent with this report, then, these other studies suggest
that YEL-AVD is more likely to be a result of a defect in innate or intrinsic immunity,
rather than in adaptive immunity. In this way, our data provide the first genetic etiology of
YEL-AVD, while strengthening the suspicion that other defects in type I IFN pathway may
underlie additional cases of YEL-AVD.
Most strikingly, these two patients harboring bi-allelic IFNAR1 variants have
survived until the ages of 9 and 14 without any clinically significant viral infections other
than the LAV-associated complications. Counter to this extremely narrow clinical
phenotype, a patient with combined partial IFNAR1 and complete IFNGR2 deficiencies
was recently reported who suffered from an HCMV infection, in addition to BCG
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disease152. However, due to the digenic defects in this patient’s innate immune system,
causal attribution of the phenotypes remains problematic. In this regard, we note that both
P1 and P2 were IgG+ and IgM- for HCMV, and HCMV DNA was not detected in their
plasma by PCR. These data confirm that P1 and P2 had been exposed to HCMV without
developing overt disease. One possible explanation for this difference would be incomplete
penetrance with respect to the HCMV susceptibility phenotype, although, given the
previous patient’s combined deficiencies in IFNAR1 (partial) and IFNGR2 (complete), a
more accurate explanation may be that this patient’s defect in type II IFN signaling was
significantly involved in the pathogenesis of his disease. This latter hypothesis would also
be consistent with the occurrence of HCMV disease in a few patients with complete
IFNGR1 or IFNGR2 deficiency153–156. We advance three hypotheses which may explain
the surprisingly robust anti-viral defense in the two patients with AR complete IFNAR1
deficiency; first, the IFNAR1 splice allele is hypomorphic in at least some cell types that
were not tested, and in which some type I IFN signaling is preserved. Second, IFNAR1 is
redundant for some type I IFNs, for at least some ISGs, analogous to signaling through the
IFN-b-IFNAR1 complex described in mice157. Lastly, a third hypothesis is that IFNAR1
and all type I IFNs are redundant for immunity against most viruses, at least in certain
conditions of infection. In this context, it is worth considering patients with IFNAR2,
STAT2, or IRF9 deficiency, which impair responses to type I IFNs, and responses to type
III IFNs in the cases of STAT2 and IRF9 deficiency. These patients are demonstrate normal
resistance to a broad range of viruses, including HCMV, and have frequently survived until
5-11 years of age49–52,125. Conversely, all patients with complete STAT1 deficiency, and
therefore impaired responses to type I, type II, and type III IFNs, died by 2 years of various
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viral or bacterial infections, unless they had received both hematopoietic stem cell
transplantation and IgG substitution29,112,116,158. Through future studies describing patients
with similar defects in innate immunity, we hope to address these hypotheses, to better
understand the mechanisms of protective immunity to viruses, and to develop safer
vaccines against viral diseases to accommodate patients with inborn errors of type I and/or
type III IFNs.
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Figure 3.1. Three private IFNAR1 variants are present in two kindreds associated
with life-threatening LAV vaccine disease. (A) Pedigrees of the IFNAR1-deficient
families. Double lines connecting two parents indicate consanguinity. The probands are
indicated by an arrow. Filled shapes identify affected individuals while open shapes
identify unaffected individuals. Asterisks demarcate those individuals who received
vaccination against YFV. The pregnancy of a third sibling in pedigree 1 (homozygous for
the same mutation as P1) was terminated at 16 weeks of gestational age. (B) CT scan of
P2’s chest demonstrating pleural effusions and atelectasis following YF vaccination (red
arrow). (C) Schematic illustration of the IFNAR1 gene with 11 coding exons and of the
IFNAR1 protein with its 4 fibronectin type-III subdomains (SD1-4). The signal peptide is
denoted “SP” and the transmembrane domain “TM”. The exons are numbered in roman
numerals (I-XI). The previously reported IFNAR1 variant is indicated in blue, while those
of P1 and P2 are indicated in red. (D) Population genetics of homozygous coding missense
and predicted loss of function IFNAR1 mutations taken from GnomAD and in-house
cohorts. The patients’ variants are private and shown in red and green, while seven variants
detected in gnomAD are shown in black. (CADD: Combined Annotation Dependent
Depletion; MAF: Minor allele frequency; MSC: Mutation Significance Cutoff).
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Figure 3.2. Impact of IFNAR1 variants on type I IFN signaling. (A) cDNA sequencing
results demonstrate aberrant splicing of IFNAR1 mRNA from patients’ SV40-F cells. The
percentage of positively identified transcripts is indicated. At least 150 transcripts were
sequenced for each individual. The black numbers under the schematic representations
indicate the positions of the included elements relative to their start sites. Results are
representative of two experiments. (B) Western blot of IFNAR1 in HEK293T cells
transiently transfected with IFNAR1 constructs; GAPDH was used as a loading control. A
representative blot from three experiments is shown. (C) Western blot of endogenous
IFNAR1 in SV40-F cells from three healthy controls (C1, C2, and C3), P1, P2, IRF7deficient (IRF7 -/-), IFNGR2-deficient (IFNGR2 -/-), TYK2-deficient (TYK2 -/-), STAT1deficient (STAT1 -/-), STAT2-deficient (STAT2 -/-), IRF9-deficient (IRF9 -/-), and
IFNAR2-deficient (IFNAR2 -/-) patients. A representative blot from three experiments is
shown. (D & F) Mean fluorescence intensity (MFI) of IFNAR1 staining on SV40-F (D)
and B-LCL (F) cells from three healthy controls (C1, C2, and C3 or T1, T2, and T3), P1,
P2, IRF7-deficient (IRF7 -/-), IFNGR2-deficient (IFNGR2 -/-), IFNGR1-deficient
(IFNGR1 -/-), TYK2-deficient (TYK2 -/-), STAT1-deficient (STAT1 -/-), STAT2deficient (STAT2 -/-), and IRF9-deficient (IRF9 -/-) patients as assessed by flow
cytometry. Mean (n=3) and SEM are shown. (E) Western blot analysis of phosphorylated
STAT1 (pSTAT1) and STAT2 (pSTAT2) levels in SV40-F cells stimulated with 1000
U/ml of IFN-α2b or -γ for 20 minutes. Cells were from two healthy controls (C1, C2), P1,
P2, IFNGR2-deficient (IFNGR2 -/-), STAT1-deficient (STAT1 -/-), STAT2-deficient
(STAT2 -/-), and IFNAR2-deficient (IFNAR2 -/-) patients. A representative blot from two
experiments is shown. (G) Transcription levels of MX1, IFIT1, and CXCL9 assessed by
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qRT-PCR on SV40-F cells treated with 1000 U/ml of either IFN-α2b, -b, or -γ for 2 hours.
Cells were from three healthy controls (C1, C2, and C3), P1, P2, IRF7-deficient (IRF7 -/), IFNGR2-deficient (IFNGR2 -/-), TYK2-deficient (TYK2 -/-), STAT1-deficient (STAT1
-/-), STAT2-deficient (STAT2 -/-), IRF9-deficient (IRF9 -/-), and IFNAR2-deficient
(IFNAR2 -/-) patients. Mean (n=3) and SEM are shown.
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Figure 3. IFNAR1 is required for type I IFN-mediated cell intrinsic immunity to viral
infections. (A) VSV titers in SV40-F cells unstimulated (left) or pre-treated (right) with
1000 U/ml IFN-α2b for 16 hours, followed by VSV infection at an MOI of 3. Cells from
three healthy controls were included (C1, C2, and C3), as well as those from P1, P2, IRF7deficient (IRF7 -/-), STAT1-deficient (STAT1 -/-), STAT2-deficient (STAT2 -/-), IRF9deficient (IRF9 -/-), and IFNAR2-deficient (IFNAR2 -/-) patients. Mean (n=3) and SEM
are shown. (B) YFV titers in SV40-F cells unstimulated (left) or pre-treated (right) with
1000 U/ml IFN-b for 16 hours, followed by infection with YFV-17D at MOI = 0.05. Mean
and range (n=2) are shown. Cells from three healthy controls were included (C1, C2, and
C3), as well as those from P1, P2, IRF7-deficient (IRF7 -/-), STAT1-deficient (STAT1 -/), STAT2-deficient (STAT2 -/-), IRF9-deficient (IRF9 -/-), and IFNAR2-deficient
(IFNAR2 -/-) patients. (C) Transcription levels of MX1, IFIT1, and CXCL9 assessed by
qRT-PCR on SV40-F cells treated with 1000 U/ml of IFN-α2b, -b, or -γ for 2 hours. Cells
were from a healthy control, P1, P2, and an IFNAR2-deficient patient that were either
transduced with WT IFNAR1, WT IFNAR2, or an empty vector. Mean (n=3) and SEM are
shown. (D) SV40-F cells were infected with YFV-17D at an MOI of 0.05 and the percent
of cells positive for YFV viral proteins was assessed by flow cytometry. Cells were from
a healthy control, P1, P2, and an IFNAR2-deficient patient (IFNAR2 -/-) and were
transduced with either WT IFNAR1, WT IFNAR2, or an empty vector (EV), and stimulated
with 1000 U/ml IFN-b for 16 hours prior to infection. Mean and range (n=2) are shown.
(E) SV40-F cells were infected with MeV at an MOI of 0.1 and viral titer was assessed at
the given time points. Cells were from a healthy control, P1, P2, and an IFNAR2-deficient
patient (IFNAR2 -/-) and were transduced with either WT IFNAR1, WT IFNAR2, or an
empty vector (EV), and stimulated with 1000 U/ml IFN-α2b for 16 hours prior to infection.
Mean and SEM (n=3) are shown.
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Table 3.1. Patients suffering from MMR vaccine-related disease. Patients with known
defects in the type I IFN signaling pathway who are reported to have experienced LAV
vaccination are described here. Their age at development of MMR disease, last known
follow-up, and clinical course are summarized.
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Genetic
Defect

Age at
first MMR
infection
(months)

STAT2 P151

18

Age (years)
at last known
followup
(deaths
indicated by
*)
5

STAT2 P2,
P352

12, 13

3, 2.5

STAT2 P4,
P550

24, 18

7*, 11
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Clinical manifestations

P1: 6 d following MMR vaccination,
the patient developed fever, rash,
conjunctivitis, and lymphadenopathy,
followed by hepatitis and pneumonitis
requiring supplemental oxygen. Patient
recovered from MMR infection.
P2: 1 wk after MMR vaccination, the
patient developed a febrile illness.
Readmitted 1 mo later with opsoclonusmyoclonus and lymphocytes in the
CSF. Readmitted again at 2.5 yrs with
impaired renal and liver function,
opsoclonus-myoclonus, and seizures.
Patient recovered from MMR infection.
P3: 1 wk after MMR vaccination, the
patient developed a febrile illness,
anemia, and lymphopenia. CSF was
positive for mumps virus by PCR.
Readmitted at 15 mo due to persistent
fever
and
malaise,
eventually
developed septic shock and metabolic
acidosis. Patient recovered from MMR
vaccination.
P4: 1 wk after MMR vaccination, the
patient developed a morbilliform rash,
tonsillitis,
conjunctivitis,
lymphadenopathy,
hepatosplenomegaly, and arthritis.
Patient recovered from MMR infection.
Patient experienced frequent severe
viral infections during the first 3 yr and
died at 7 yr of fulminant viral infection.
P5: 1 wk after MMR vaccination, the
patient
developed
disseminated
measles, complicated by hepatitis and
pneumonitis. Patient recovered from
MMR infection.

IFNAR249

13

1.4*

IRF741

12

9

IRF9125

16

5

STAT1116

13

2

IFNAR1 P1
(this report)

12

9

6 d after MMR vaccination, the patient
developed a marked injection-site
reaction and generalized morbilliform
skin rash, recurrent maculopapular
rash, fever, and intractable seizures.
Patient died on 81 d after vaccination.
1 wk after MMR vaccination, the
patient developed a rash suggestive of
measles. Patient recovered from MMR
infection. Patient also suffered from a
life-threatening influenza infection at 3
yr.
2 wk after MMR vaccination, the
patient developed an idiopathic biliary
perforation. Patient recovered from
MMR infection. Patient also suffered a
life-threatening influenza infection at 2
yr, parainfluenza virus at age 4, and
recurrent fevers without a causative
pathogen identified throughout her
childhood.
1 week after MMR vaccination, patient
developed fever, irritability, rash, and
diarrhea, encehpalitis, hemophagocytic
lymphohistiocytosis-like
syndrome,
and was positive for human herpesvirus
6. Patient was readmitted 7 d later with
refusal to walk, unsteady gait, and
inflammatory cells in the CSF. Patient
recovered from MMR infection.
10 d after MMR vaccination, patient
developed a generalized exanthema,
fever, and encephalitis. Patient
recovered from MMR infection.
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Figure 3.S1. Evidence of YFV virus infection in P2. Sanger sequencing alignments
demonstrating an identical insertion in the YFV genome recovered from P2 during her
infection. The consensus WT YFV sequence is shown in the top row, while two YFV-17D
strains (102_84 and YF993FV013Z) sequenced are directly below that, followed by the
sequence from the YFV isolated from the patient (RNA_2882). Environmental YFV
isolates are shown in the bottom four rows.
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Figure 3.S2. Genetic analysis of IFNAR1 deficient patients. (A) Sanger sequencing
chromatograms demonstrating c.674-2A>G, c.674-1G>A, and c.783G>A mutations in
patient DNA (black arrows). (B) Agarose gel electrophoresis of IFNAR1 cDNA products
generated from patient mRNA transcripts. The upper image shows subtle changes in the
size of the full-length transcript (expected length of 1674 base pairs), while the bottom
image demonstrates that additional alternatively spliced mRNAs can be detected at low
abundances when only exons IV through VII are amplified, as depicted schematically in
C. Numbers in blue correspond to the structure of the transcripts present in a given band,
as diagrammed in figure 2A, with nucleotide lengths in parentheses. Representative image
from two experiments. (C) Diagram of the IFNAR1 gene in the region containing exon 6.
Exons are depicted with boxes, while introns are depicted with lines. mRNA transcripts
from this region were amplified by PCR and inserted into the pGEM-T Easy system.
Mutations present in patient cells are indicated with vertical red lines. Primers used in
cDNA

sequencing

are

demonstrated

ATAGCTTAGTTATCTGGAAAAACTCTTCAGGTG-3’,

F;

(5’5’-

GGGTAGTTTTGACATTTTCACAGTCAGG-3’, R), and the nucleotide lengths of the
features are shown in parentheses. (D) qRT-PCR measuring IFNAR1 mRNA levels in
SV40-F cells from P1, P2, three healthy controls (C1, C2, and C3), IRF7-deficient (IRF7 /-), IFNGR2-deficient (IFNGR2 -/-), TYK2-deficient (TYK2 -/-), STAT1-deficient
(STAT1 -/-), STAT2-deficient (STAT2 -/-), IRF9-deficient (IRF9 -/-), and IFNAR2deficient (IFNAR2 -/-) patients. IFNAR1/GUS mRNA ratios are shown after normalization
to C1. Mean (n=3) and SEM are shown.

77

78

Figure 3.S3. Disrupted function of the type I IFN signaling pathway in patient cells.
(A) Western blot of endogenous IFNAR1 in B-LCL cells from three healthy controls (T1,
T2, and T3), P2, IRF7-deficient (IRF7 -/-), IFNGR1-deficient (IFNGR1 -/-), TYK2deficient (TYK2 -/-), STAT1-deficient (STAT1 -/-), STAT2-deficient (STAT2 -/-), IRF9deficient (IRF9 -/-), and IFNAR2-deficient (IFNAR2 -/-) patients; GAPDH was used as a
loading control. A representative blot from three experiments is shown. (B & D) IFNAR2
mean fluorescence intensities (MFI) from patient SV40-F (B) and B-LCL (D) cells stained
with an anti-IFNAR2 fluorescent antibody. Cells were from three healthy controls (C1, C2,
and C3 or T1, T2, and T3), P1, P2, IRF7-deficient (IRF7 -/-), IFNGR2-deficient (IFNGR2
-/-), IFNGR1-deficient (IFNGR1 -/-), TYK2-deficient (TYK2 -/-), STAT1-deficient
(STAT1 -/-), STAT2-deficient (STAT2 -/-), IRF9-deficient (IRF9 -/-), and IFNAR2deficient (IFNAR2 -/-) patients and were assessed by flow cytometry. Mean (n=3) and
SEM are shown. (C) Western blot of IFNAR1 in SV40-F cells from a healthy control, P1,
P2, and an IFNAR2-deficient (IFNAR2 -/-) patient transduced with WT IFNAR1, WT
IFNAR2, or an empty vector; GAPDH was used as a loading control. A representative blot
from two experiments is shown. (E) Mean fluorescence intensities (MFI) of SV40-Fs from
a healthy control, P1, P2, and an IFNAR2-deficient (IFNAR2 -/-) patient and transduced
with WT IFNAR1, WT IFNAR2, or an empty vector (EV) and stained with an anti-IFNAR1
antibody. Mean (n=3) and SEM are shown. (F & H) Survival rates following VSV infection
of primary fibroblasts either untreated (F) or pre-treated (H) with 1000 U/ml IFN-α2b for
24 hours prior to infection. Cells were from a healthy control, P1, and an IFNAR2-deficient
patient that were either transduced with an empty vector (EV), WT IFNAR1 (IFNAR1), or
WT IFNAR2 (IFNAR2). Mean (n=3) is shown. (G) IFN-β levels detected in the supernatant
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of SV40-F cells either 0 or 24 h after infection with YFV-17D. Cells from two healthy
controls (C1 and C2), P1, P2, an IRF7 deficient patient (IRF7 -/-), and a STAT1-deficient
patient (STAT1 -/-) were included. The limit of quantitation (LOQ) is indicated by a dotted
line. Mean (n=2) and range are shown.
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Figure 3.S4. IFNAR1 is essential for type I IFN-mediated intrinsic immunity to
multiple viruses. (A & B) HSV-1-GFP replication levels, as assessed by GFP intensity, in
SV40-F cells unstimulated (A) or pre-treated (B) with 1000 U/ml IFN-α2b followed by
infection with HSV-1-GFP (MOI=0.01). Cells from three healthy controls were included
(C1, C2, and C3), as well as those from P1, P2, IRF7-deficient (IRF7 -/-), STAT1-deficient
(STAT1 -/-), STAT2-deficient (STAT2 -/-), IRF9-deficient (IRF9 -/-), and IFNAR2deficient (IFNAR2 -/-) patients. Mean (n=2) and range are shown. (C & D) HSV-1 titers
in SV40-F cells unstimulated (C) or pre-treated (D) with 1000 U/ml IFN-α2b for 16 hours,
followed by infection with HSV-1 (MOI=0.01). Mean and range (n=2) are shown. Cells
from three healthy controls were included (C1, C2, and C3), as well as those from P1, P2,
IRF7-deficient (IRF7 -/-), STAT1-deficient (STAT1 -/-), STAT2-deficient (STAT2 -/-),
IRF9-deficient (IRF9 -/-), and IFNAR2-deficient (IFNAR2 -/-) patients. (E & F) IAV titers
in SV40-F cells unstimulated (E) or pre-treated (F) with 1000 U/ml IFN-α2b for 16 hours,
followed by infection with (A/H1N1/CA/2009) IAV at MOI=1. Cells from three healthy
controls were included (C1, C2, and C3), as well as those from P1, P2, IRF7-deficient
(IRF7 -/-), STAT1-deficient (STAT1 -/-), STAT2-deficient (STAT2 -/-), IRF9-deficient
(IRF9 -/-), and IFNAR2-deficient (IFNAR2 -/-) patients. Mean (n=2) and range are shown.
(G & H) SV40-F cells stimulated for 16 hours with 1000 U/ml IFN-b prior to infection (H)
or left untreated (G) were infected with 100 µl of YFV Asibi and viral titer was assessed
by plaque assay on Huh7.5 cells at the given time points. Mean and range (n=2) are shown.
Different time points represent independent infections. SV40-Fs from a healthy control,
P1, P2, and an IFNAR2-deficient (IFNAR2 -/-) patient were included. (I & J) SV40-F cells
stimulated for 16 hours with 1000 U/ml IFN-b prior to infection (J) or left untreated (I),
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were infected with ZIKV (MOI = 0.05) and viral titer was assessed by plaque assay on
Vero cells at the given time points. Mean and range (n=2) are shown. Different time points
represent independent infections. SV40-Fs from a healthy control, P1, P2, and an IFNAR2deficient (IFNAR2 -/-) patient were included.
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Table 3.S1. Rare homozygous or possible compound heterozygous variants found by
exome sequencing of P1 and P2. Genes listed in red are homozygous while those in black
may be compound heterozygous or may occur on the same allele. † indicates a gene
containing a stop-gain mutation, while ‡ indicates a gene that is predicted to be related to
primary immunodeficiencies via a connectome analysis100. The consequences of the
variations on coding sequences are given in parenthesis following each gene.
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P1
URI1 (c.840_842delTGA)

P1 (cont.)
KIRREL2 (c.32_34delTCC)

CNTF (c.T101A, c.T494G)

CNTD2 (c.T524A)

SLC45A1
(c.130_131insCGGGAGATG)

ACSL3 (c.G1043A)

HTR2B (c.T848C)

MAFA (c.621_623delTGG)

MTMR9 (c.T1153A)

TMPRSS13 (c.248_262del
GGGCTGGAGATGCCT)

PSG11 (c.G44C)
MEOX2‡ (c.228_230delTGG)

DYTN (c.C679T)
THAP11
(c.367_369delCAG)
CXorf23
(c.1727_1728delTA)
TMEM54 (c.G136A)
NLRP10 (c.T752C)
SESTD1 (c.A1310G)

CLN8 (c.A806T)
CNDP1 (c.43_44insTGC)
MPRIP (c.534_539delCAGCAG)
TMEM247
(c.382_383insAGCGGCAGCAC
GAGGTGGTGATGGAGCAGC
TGCAGCGGG)
FADS6
(c.17_18insGATGGAACCTACG
GAGCCCATGGAACCTACGG
AGCCCATGGAACCTACGGA
GCC)
KIAA2018
(c.4410_4418delTGCTGCTGC)
ZNF407 (c.A515T, c.C4145T)
SMPD1‡
(c.108_113delGTCGGC)
TBL1Y (c.G274A)
AOX1 (c.G173A)
BSN (c.G11015A)
MAP3K4‡ (c.3566_3568delCTG)
ATG3 (c.920dupT)

APEX1‡ (c.953_954delTG)

DLC1‡ (c.G161T)
PLBD1 (c.74_76delGCA)
ANKRD62 (c.G1197C)
MAML3‡ (c.1506delG)
RBM23
(c.1077_1078insGCC)
HOXD9‡
(c.794_795insGCA)
DCP1B (c.782_783insGCA,
c.C1532T)
IFNAR1‡ (c.674-2A>G)
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P2
KCNN3
(c.G1092C)
KIAA1875WDR97
(c.3123+1G>T,
c.4750G>A)
MADCAM1(c.
736_737insAG
GAG)
IFNAR1†‡
(c.674-1G>A,
c.G783A)
PIWIL3
(c.A2629C,
c.A1996G)

Chapter 4:
Conclusions and future experiments
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In my thesis research, I explored the human genetic basis of severe viral diseases
in patients with inborn errors of the type I IFN signaling pathway. Unlike bacterial or fungal
pathogens, viruses largely utilize the replication machinery of their hosts to multiply,
exacerbating the challenge of the self/non-self conundrum at the heart of immunology.
Similarly, this ability of viruses to repurpose host proteins and systems has made the
development of therapeutics against viruses more difficult than has been the case for the
development of antibacterials or antifungals, for example. In order to effectively treat viral
diseases, it is therefore critical that we understand acutely the functions of viral effectors
and how they interact with our own cells.
The experiments described herein provide striking evidence that both common and
rare viral diseases may have unappreciated genetic etiologies. Notable in this regard is the
discovery of AR IRF9 deficiency as a genetic basis for life-threatening influenza infections,
adding to a still-growing list which includes AR IRF7, AD GATA2, and AD TLR3
deficiencies41,64,68. The clustering of these defects in genes related to both type I and type
III IFN signaling, but not either individually, is also remarkable. Although initially thought
to be largely redundant to type I IFNs, except with expression restricted to epithelial
surfaces, type III IFNs have more recently been suggested to have unique functions,
possibly as a consequence of altered transcriptional responses manifesting, at least partly,
as a more evenly balanced pro- and anti-inflammatory responses91,159–161. The absence of
severe influenza infections in patients lacking either type I or type III IFN receptors in
isolation may indeed suggest that, in natura, both pathways are sufficient for control of
viral replication. In mice, type III IFNs are thought to be the first IFNs produced following
influenza challenge and they activate epithelial anti-viral immunity without the
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inflammation associated with type I IFN activity161. Taken together, the available data in
humans support a similar schema whereby type III IFNs are initially responsible for
restricting IAV replication, with type I IFN becoming activated only when high viral
burdens lead to escape from type III IFN control. Should this rule continue to hold in other
cases of life-threatening influenza infections, treatment with type I and/or III IFNs may be
of limited use. Instead, it may be more productive to identify the downstream restriction
factors which are directly responsible for control of IAV replication and consider
alternative mechanisms of inducing these factors, or otherwise mimicking their effects.
Importantly, for patients with a known genetic etiology for severe influenza infections,
prophylaxis via routine vaccination may likely be sufficient (as in the case of the IRF7
deficient child), although IVIgs may provide additional benefits. Further identification of
genetic etiologies for severe influenza infection is certain to supplement our understanding
of innate immunity while also focusing the development of anti-influenza or anti-viral
therapeutics.
Conversely, the surprisingly narrow clinical phenotype of the two IFNAR1
deficient patients immediately confronts us with a profound medical mystery: how could
patients with complete loss-of-function defects in such a critical pathway have survived
until the ages of 9 and 14 while continuing to thrive? The most obvious hypothesis,
although still exceptionally surprising, is that type I IFN related immunity is largely
redundant for defense against environmental viruses in humans. Consistent with this
hypothesis, the only currently described patient with AR IFNAR2 deficiency suffered a
fatal encephalitis following routine inoculation with the MMR vaccine, but demonstrated
no issue controlling respiratory viruses or CMV, with which they had also been infected.
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This disconnect between cellular and clinical phenotypes is reminiscent of other PIDs, such
as MyD88 or IRAK4 deficiencies, in which network redundancy or adaptive immunity
combine to produce a relatively specific clinical phenotype162,163. Analogously, we might
view the type I IFN response as a global anti-viral “fail-safe”, with tissue-specific innate
immunity coordinating with adaptive immunity to form the first line of defense. It is also
possible that, rather than following from non-redundancy between type I and III IFNs, the
patients’ clinical specificity is due to non-redundancy with the type I IFN signaling
pathway itself.
The type I IFNs are a family of pleiotropic cytokines encompassing 17 distinct
proteins in humans that can further be divided into 13 IFN-αs, IFN-β, IFN-κ, IFN-ε, and
IFN-ω. Intriguingly, the human type I IFNs all signal through the same heterodimeric
receptor, all lack introns, and all are located on the short arm of chromosome 9. The
abundance of distinct IFNs that seem functionally indistinguishable from one another has
long been a mystery in the field of innate immunity. Recent work, especially that carried
out by Paul Hertzog’s group, has suggested there may be subtle functional differences
between the type I IFNs. In mice, for example, IFN-ε is confined to the epithelium of the
female reproductive tract where it is constitutively expressed and protects against viral and
bacterial infections164. Unlike other IFNs, IFN-ε expression is hormonally regulated and
was not induced by known pattern-recognition receptor (PRR) pathways164. Perhaps even
more surprisingly, this group also demonstrated that a unique IFNAR1-IFN-β complex
could assemble and productively signal in murine peritoneal exudate cells164. Given the
evolving appreciation of non-redundancy among the various type I IFNs, another plausible
explanation for the lack of overt disease in P1 and P2 is that one or more type I IFNs may
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be able to coordinate with IFNAR2 in the absence of IFNAR1 and initiate an anti-viral
program. The third hypothesis we advance to explain this mystery is that the patients’ splice
alleles are hypomorphic and that, among the hundreds of cell types within the body, some
are able to generate correctly spliced IFNAR1 transcripts, leading to expression of a
functional protein and intact signaling in the type I IFN pathway. Even if the last hypothesis
were found to be correct, the lack of IFN signaling we consistently observed in both
lymphoid and myeloid compartments would still suggest further consideration of the first
two hypotheses. In this way, our work highlights inter- and intra-network redundancies
related to the type I and III IFN signaling pathways which lie at the heart of genetic
susceptibility to severe viral infections.
In conclusion, the findings of my thesis could be extended in multiple ways. The
identification of additional genetic etiologies for the conditions described herein will not
only augment the growing body of literature demonstrating the human genetic basis of
infectious diseases but will also clarify our mechanisms of anti-viral immunity. Innate
immunity has armored us with a system of partially overlapping defenses whose subtlety
and independence we are only beginning to grasp. The discovery of additional experiments
of nature will allow us to untangle the unique aspects of the type I and III IFN signaling
pathways, in addition to defining the aspects they share. With an improved understanding
of innate immunity, we may expect to more ably treat the existing patients with severe viral
diseases, as well as to develop additional methods of prophylaxis and prevent such diseases
in the future.
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EXPERIMENTAL PROCEDURES

Materials and Methods
Study Oversight
These studies were approved by the institutional review boards of The Rockefeller
University, INSERM, University Hospitals Leuven, the National Institute of Infectious
Diseases, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, or the National Institute of
Allergy and Infectious Diseases, National Institutes of Health. Written informed consent
was obtained from all patients or their guardians.
Case Reports
Chapter 2:
We report the case of a girl born in 2013 to consanguineous parents (first cousins,
f=1/16) of Algerian descent, living in France, who was admitted to intensive care with
acute respiratory distress secondary to infection with influenza A virus at the age of 23
months. According to her medical history, she was born after 39 weeks of gestation with a
birth weight of 2910 g, height of 47 cm and Apgar score 10/10. Her family history was
negative for previous severe infectious diseases.
Since the age of five months, the patient had a history of recurrent fevers (3-5 days
per month) associated with digestive features including diarrhea, abdominal pain without
any vomiting, transient cutaneous rash and intermittent urticaria, initially suggestive of an
auto-inflammatory syndrome since no infectious agent was identified. Prior to any
supportive treatment, interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNFα)
were positive, respectively at 17.9 pg/ml (0-15) and 25.1 pg/ml (0-20), whereas IL-6 and

92

IL-10 were normal and negative. MEFV, MVK, CIAS1, TRAPS were sequenced and
found without any deleterious variation. Anti c1q antibodies were consistently positive, but
sequencing of DNASE1L3 was normal.
She experienced five episodes of bronchiolitis revealing severe asthma (for which
she was prescribed montelukast, albuterol, and ipratropium bromide), gingivostomatitis
and adenitis, and four episodes of prolonged gastroenteritis. She was hospitalized in the
pediatric intensive care unit (PICU) due to idiopathic biliary perforation 14 days after
MMR vaccination at 16 months old; disseminated intravascular coagulation was suspected
secondary to thrombopenia (27,000/mm3) and low prothrombin time (40%), associated
with elevated liver enzymes (SGOT 274 UI/l and SGPT 128 UI/l). She was readmitted to
PICU two months later with a suspicion of septic shock in the absence of a detectable
pathogen, associated with elevated CRP (180 mg/l), lymphopenia (830/mm3), low platelet
count (14 000/ mm3) and low PT (66%).
At 23 months of age, she was admitted to PICU with a severe influenza A infection
resulting in acute respiratory distress syndrome requiring mechanical ventilation for six
days. Since increased oxygen was required with cPAP (FiO2 100%), she was intubated.
She developed severe acute respiratory distress syndrome, with bilateral infiltrates on chest
radiography. She was placed under mechanical ventilation in a volume support mode, with
a frequency of 35 per minute and 100% fiO2. All bacteriological and viral sputum culture
were negative, except Influenza A virus. She was administered salbutamol, ipratropium
bromide, ketamine, theophylline, magnesium sulfate, ceftriaxone and oseltamivir. The
oseltamivir treatment was stopped after five days. On the third day, bilateral parotidis and
cervical adenitis appeared and were treated by amoxicillin and clavulanic acid. She was

93

discharged from PICU after eight days, and her condition improved enough to be
discharged after 22 days of hospitalization.
Standard immunological tests were performed. Serum levels of IgG, IgA, IgM were
unremarkable. T and NK lymphocyte count were conserved, whereas a modest B
lymphocytosis was measured. Lymphocyte proliferation was normal for PHA, tuberculin
and candidin (N>50), but low in presence of tetanus, CMV and HSV antigens (N>10)
(Table S1). T and B cell counts were within normal ranges. The patient was IgG
seropositive for tetanus, diphtheria, haemophilus, measles, mumps, rubella and HBV (Ag
HBs negative, anti HBs positive, anti HBc negative) following routine vaccination. She
remained seronegative for HIV1/2, HAV, HCV, VZV, Parvovirus B19, EBV, CMV and
pneumococcus despite proper vaccination for the latter.
IVIgs at 0.4g/kg/3 weeks were begun at two years and eight months of age because
of recurrent viral infections, resulting in an improvement of her recurrent fever profile,
digestive symptoms and susceptibility to viral infection.
Since IVIgs were started, the patient has been hospitalized on two occasions: once
for acute respiratory distress secondary to metapneumovirus and once for febrile pseudoocclusive syndrome with free fluid in Morrisson’s pouch detected by sonogram secondary
to symptoms of gastro-enteritis. At that time, RNA of parainfluenza 1,2,3,4 group was
detected by PCR in the sputum but no pathogen was detected known to cause
gastroenteritis (also negative were rhinovirus/enterovirus, metapneumovirus, influenza A
and B, coronavirus, RSV A or B by PCR in the sputum, and adenovirus, norovirus,
enterovirus and rotavirus by PCR in the stool). During neither episode was she admitted to
PICU.
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Chapter 3:
Patient 1 (P1) was born in Iran to consanguineous parents. He was evaluated at the
age of one year for disseminated vaccine-strain measles. He had previously received
Hepatitis B virus (HBV), BCG and influenza vaccinations without any adverse effect. Ten
days after inoculation with the MMR vaccine, he presented with a generalized exanthem,
fever and neurological symptoms consistent with encephalitis. Laboratory findings only
showed moderate lymphocytosis with 7800 total leukocytes/uL, 29% neutrophils, 45%
lymphocytes, 10% monocytes, 4% eosinophils, and mild hyponatremia. A computed
tomography (CT) of the brain showed mild cerebral edema and analysis of CSF
demonstrated leukocytosis (350 lymphocytes/uL, 2 neutrophils/uL). PCR for measles was
positive both in blood and CSF, with negative bacterial cultures. Antibodies against
measles and mumps were at the lower limit of the normal range, isohemagglutinin titers
were normal and antibody responses to pneumococcal and HBV-antigens were also
normal. Additionally, P1 was IgG+ and IgM- for CMV, and CMV DNA was not detectable
in his plasma. Lymphocyte subpopulations (T, B and NK cells) were in the normal range.
His past medical history was characterized by frequent viral upper respiratory tract
infections with a hospital admission for bronchiolitis, but was otherwise not significant.
His growth and development were normal. His younger sister also developed
meningoencephalitis one week after receiving MMR vaccination, and died of
complications four weeks later. P1 is now 9 years old, in good health and has not
manifested any other invasive infection (Figure 1A).
Patient 2 (P2) is a 14 year-old Brazilian girl born to non-consanguineous parents.
Otherwise healthy until age 12, she presented with fever, hypotension, vomiting, and
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lethargy 7 days following YF vaccination. Laboratory findings after admission
demonstrated leukocytosis with total leukocytes at 28,200/uL, and thrombocytopenia with
a platelet count of 21,000/uL. Consistent with renal and hepatic dysfunction, the patient
was icteric on exam with an international normalized ratio (INR) of 2.0 and a partial
thromboplastin time (PTT) of 66.4. She demonstrated ALT and AST levels of 187 IU/L
and 623 IU/L, respectively, and had a creatinine of 2.71 mg/dL. Her condition rapidly
deteriorated with bradycardia and diminished consciousness with a Glasgow Coma Score
of 8, necessitating admission to the ICU, intubation, and mechanical ventilation. A CT of
the chest demonstrated pleural effusions and atelectasis (Figure 1B). Neutralizing
antibodies against YFV were detectable by plaque reduction neutralization test at a dilution
titer of 1:640, as were antibodies against herpes 1 and 2 viruses, while antibodies against
HAV, HBV, and HCV, as well as dengue virus and leptospirosis were negative. P2’s serum
was similarly IgG+ and IgM- against CMV antigens, with CMV DNA not detectable in her
plasma by PCR. YFV was detected in the patient’s blood by PCR analysis, and sequencing
confirmed that this was the vaccine-strain virus, not wild-type YFV (Figure S1). A
diagnosis of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) was made.
She was treated with an aggressive course of IV fluids, plasma and platelet transfusions,
vasopressors, hydrocortisone, and was prophylactically given IV broad spectrum
antibiotics. Her hypotension and thrombocytopenia resolved over the next week and, two
weeks after her admission, she was discharged from the ICU and made a full recovery. One
year after this episode, she remains healthy. Her circulating Ig levels and leukocyte subsets
are normal. Notably, the patient received two MMR vaccines at 12 and 16 months of age,
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and other live vaccines (oral poliovirus and bacillus Calmette-Guérin), without incident
(Figure 1A).
Whole exome sequencing
Exome capture was performed with the SureSelect Human All Exon 50 Mb kit
(Agilent Technologies). Paired-end sequencing was performed on a HiSeq 2000 (Illumina)
generating 100-base reads. We aligned the sequences with the GRCh37 reference build of
the human genome using the BWA aligner165. Downstream processing and variant calling
were performed with the Genome Analysis Toolkit, SAMtools, and Picard166,167.
Substitution and InDel calls were made with GATK Unified Genotyper. All variants were
annotated using an annotation software system that was developed in-house98,168,169.
Genetics
WES analysis of each patient revealed a total of 15,807 variants in P, 50,634
variants in P1, and 16,797 variants in P2. We filtered out all variations found in 1000
genomes database, the Genome Aggregation Database (GnomAD), our own database of
4,892 exomes for infectious diseases at a frequency of >1%, leaving 44, 48, and 11 nonsynonymous coding variants in P, P1 and P2’s exomes, respectively: 20, 30, and 6 were
homozygous while 24, 18, and 5 were heterozygous. The heterozygous variants inherited
from one parent were not considered in a model of complete penetrance. Excluding those
in IFNAR1, none of the variants affected genes known to be related to immunity. The
nonsense c.783G>A mutation had a CADD score of 37, and the two splicing mutations,
c.674-1G>A and c.674-2A>G, had CADD scores of 23.6 and 24, respectively. In the IRF9
patient, excepting 4 heterozygous and 2 homozygous variants, none of the variants affected
genes related to immunity. The IRF9 c.991G>A mutation had a CADD score of 32.21. A
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genomic measure of individual homozygosity was plotted for the three patients, two
European individuals from consanguineous families, and 37 individuals from nonconsanguineous families from our in-house WES database. Homozygosity was computed
as the proportion of the autosomal genome belonging to runs of homozygosity (ROHs).
The ROHs were defined as ranging at least 1 Mb of length and containing at least 100
SNPs, and were estimated using the homozyg option of the PLINK software170. The
centromeres were excluded because they are long genomic stretches devoid of SNPs and
their inclusion might inflate estimates of homozygosity if both flanking SNPs are
homozygous. The length of the autosomal genome was fixed at 2,673,768 kbs as previously
described171. We estimated the selective pressure acting on IFNAR1 to be 2.762 (indicative
of positive selection), by estimating the neutrality index (NI) at the population level:
(PN/PS)/(DN/DS), where PN and PS are the number of non-synonymous and synonymous
alleles, respectively, at population level (1000 Genomes Project) and DN and DS are the
number of non-synonymous and synonymous fixed sites, respectively, for the coding
sequence of IFNAR1172. We estimated the selective pressure acting on IRF9 to be 0.088
(indicative of purifying selection) with the same method.
Cells
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque
density gradient (Lymphoprep, Proteogenix) from the blood of patients and healthy donors.
SV40-immortalized dermal fibroblasts, HEK293-T cells, and Vero cells were maintained
in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine
serum. B-LCLs were grown in Roswell Park Memorial Institute (RPMI) 1640 medium
supplemented with 10% fetal bovine serum. Primary fibroblasts were grown in DMEM/F-
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12 (1:1) containing L-glutamine and Hepes supplemented with 10% fetal calf serum,
amphotericin B (0.5 µg/ml), penicillin (100 U/ml) and streptomycin (100 µg/ml). For
chapter 2, Stably-transfected dermal fibroblasts were obtained by transfecting
pTRIPIRF9iresRFP using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s protocol. Stable transfectants were selected by puromycin treatment
(0.3ug/mL) and subsequent fluorescence activated cell sorting for RFP-expressing cells
yielding >90% RFP+ fibroblasts. Transfection of HEK293-T cells with IFNAR1 constructs
in pCAGG-S was also accomplished using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s protocol.
YFV Plaque Reduction Neutralization Test
Serum samples were used to quantify the levels of neutralizing antibodies specific
to the 17DD-YF virus employing the micro plaque reduction neutralization test (microPRNT50). The assays were performed at Laboratório de Tecnologia Virológica, BioManguinhos (LATEV, FIOCRUZ-RJ, Brazil). First, a viral suspension was prepared with
YF 213/77 #002/16, diluted previously with the objective to obtain approximately 30 lysis
plaques per well. Prior to neutralization, the serum sample was inactivated at 56°C for 30
min and submitted to serial 2-fold dilutions (1:5 – 1:640), and afterwards about thirty
plaque-forming units (pfu) of yellow fever virus suspension was added to the samples in
96 well tissue culture plates. After addition of virus, the plates were incubated for 1 hour
at 37°C in an incubator with 5% CO2. A 50 ul cell suspension with 1,600,000 cells/ml were
inoculated in all 96 wells of the plate and incubated at 37°C for 3 h under 5% CO2 for
adsorption/sedimentation. The media was then discarded and carboxymethylcellulose
(2.5%) added and the cells were incubated for 6 days at 37°C with 5% CO2. After
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incubation, the plates were fixed in formaldehyde (5%) for at least 1 hour at room
temperature and stained with 2% crystal violet for 30 minutes at room temperature. Both
steps were followed by cleansing with running water.
The arithmetic mean of all viral plaques obtained without serum were estimated.
From the mean, the 50% endpoint of the number of plaques was calculated. Afterwards,
using the dilution with plaque numbers immediately above and below the endpoint, the
serum dilution that would result in the 50% endpoint was estimated by linear regression.
The result were expressed in reciprocals of dilution.
Measurement of antibodies against diphtheria, tetanus, rubella and measles
An

enzyme-linked

immunosorbent

assay

(ELISA)

standardized at

the

Immunological Technology Laboratory of Bio-Manguinhos (LATIM, FIOCRUZ-RJ,
Brazil) was used for antibody measurement. Standard diphtheria and tetanus curves were
prepared using in house sera titrated against National Institute for Biological Standard
Controls in England (NIBISC) International References. The diphtheria and tetanus
antigen for coating ELISA plates were obtained from NIBISC. Anti-diphtheria and antitetanus ELISA titers were considered to be protective if they were equal to or higher than
the cut-off of 0.1 IU/ml. Serum titers were calculated by four parameter logistic curve using
SoftMax Pro, version 5.2 (Molecular Devices, USA)173.
The ELISA tests for rubella and measles antibodies were performed at the
Respiratory Virus Laboratory of Instituto Oswaldo Cruz (FIOCRUZ-RJ, Brazil) utilizing
the kits Anti-Measles Vírus ELISA (IgG) and Anti-Rubella Virus ELISA (IgG)
(EUROIMMUN, Germany) according to manufacturer instructions. Anti-Measles and
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anti-Rubela ELISA titers were considered to be positive if they were equal to or higher
than the cut-off of 275 IU/ml and 11 IU/ml respectively.
Plasmids
IFNAR1 or IRF9 cDNA were cloned into the pGEM-T cloning vector (Promega,
Madison, WI, USA). Site-directed mutagenesis was performed to obtain the indicated
mutant

constructs.

All

IRF9

constructs

were

then

subcloned

into

the

pTRIP.CMV.IVSb.iresTagRFP_Dest vector using Gateway cloning technology (Life
Technologies), while IFNAR1 constructs were subcloned into pCAGGS for overexpression
studies. For lentiviral vector production utilized in chapter 3, lentiviral vector transfer
plasmids pCH_EF1a_IFNaR1_IRES_Bsd and pCH_EF1a_IFNaR2_IRES_Bsd were
generated by cloning the codon optimized coding sequence for human IFNAR1 isoform 1
(NM_000629 or NP_000620) and human IFNAR2 into the multiple cloning site of the HIVbased lentiviral vector transfer plasmid pCH_EF1a_MCS_IRES_Bsd. Both cDNAs were
ordered as a gBlock (IDT Haasrode, Belgium). Sequences were cloned in frame with the
IRES-Bsd sequence. All constructs were resequenced to ensure no adventitious mutations
were generated during the cloning.
Production of IFNAR1 and IFNAR2 lentiviral vectors
HIV-based viral vectors were produced by the Leuven Viral Vector Core as
previously described (Ibrahimi et al. Hum Gene Therapy, 2009), by triple transient
transfection of 293T cells with a Vesicular Stomatitis Virus Glycoprotein G envelope
encoding plasmid, and a packaging plasmid together with the respective transfer plasmids
using polyethylenimine (Polysciences, Amsterdam, The Netherlands), resulting in
LV_IFNAR1, LV_IFNAR2 and LV_control (empty vector), respectively. After collecting
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the supernatant, the medium was filtered using a 0.45-µm filter (Corning Inc, Seneffe,
Belgium) and concentrated using a Vivaspin 50,000 MW column (Vivascience, Bornem,
Belgium). The vector containing concentrate was aliquoted and stored at -80°C.
Generation of stably reconstituted cell lines
HIV-based vectors were used to transduce primary fibroblasts, in a serial dilution
series. Cells were cultured and subjected to blasticidin selection (5 µg/ml). IFNAR1
expression was corroborated by qRT-PCR, WB, and cell surface staining.
Western blotting
Fibroblasts, with or without pretreatment with IFN-α2b (Schering, Kenilworth, NJ,
USA) or IFN-𝛾 (Imukin, Boehringer Ingelheim) for the specified times, were lysed in NP40
lysis buffer (280mM NaCl, 50mM Tris pH 8, 0.2mM EDTA, 2mM EGTA, 10% glycerol,
0.5% NP40) supplemented with 1mM DTT, PhosSTOP (Roche, Mannheim, Germany) and
Complete protease inhibitor cocktail (Roche, Mannheim, Germany). 40 ug protein lysate
per lane was resolved by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF)
membrane, which was probed with unconjugated primary antibodies and HRP-conjugated
secondary antibodies. An anti-GAPDH (Santa Cruz) antibody was used as a loading
control. IRF9 was probed with antibody recognizing the carboxy-terminus at a dilution of
1:1000 (ISGF-3γ p48 (H10), Santa Cruz Biotech). Endogenous IFNAR1 was probed with
an antibody recognizing the amino-terminus at a dilution of 1:1000 (64G12, generously
provided by Sandra Pellegrini), while a polyclonal anti-IFNAR1 was used to detect
overexpressed protein (AP8550c, ABGENT, San Diego, CA, USA). SuperSignal West
Femto Chemiluminescent substrate (Thermo Fisher Scientific) was used to visualize HRP
activity, and this signal was detected by an Amersham Imager 600 (GE Life Sciences).
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For knockdown studies of IRF9, knockdown efficiency was determined by
immunoblotting. 30ug of total protein loaded per lane were separated on 4-12% NuPAGE
Bis-Tris SDS-PAGE gels (Invitrogen), and then transferred onto nitrocellulose membranes
using Trans-Blot Turbo Transfer System (Bio-Rad Laboratories). After blocking with 5%
nonfat dry milk (Bio-Rad Laboratories) in PBS containing 0.1% Tween 20 (SigmaAldrich), membranes were blotted with the IRF9 antibody (ISGF-3γ p48 (H10), Santa Cruz
Biotech), MAVS (clone #3993; Cell Signaling Technologies), or HSP90 (clone 68; BD),
followed by incubation with appropriate HRP-conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories) and SuperSignal West Pico Chemiluminescent substrate
or SuperSignal West Dura Extended Duration Substrate (Thermo Fisher Scientific). Signal
was detected by ChemiDocTM Touch Imaging System (Bio-Rad Laboratories).
Flow Cytometry
For measuring surface expression on patients’ cells, B-LCL and SV40-F cells (5 x
105 cells per well) were plated in 96-well plates and surface-stained with either purified
mouse anti-IFNAR1 AA3 (provided by Sandra Pellegrini) or PE mouse anti-IFNAR2 (PBL
Assay Science, Piscataway, NJ, USA) antibodies. Cells stained with AA3 were then
washed once with PBS and incubated with a biotinylated rat anti-mouse secondary
(Thermo Fisher Scientific) for 30 minutes before being washed once with PBS and
incubated for 30 minutes with a PE-conjugated streptavidin (Thermo Fisher Scientific).
The cells were then washed twice with PBS and analyzed by flow cytometry. Data were
acquired on an LSRII flow cytometer (BD), and the results were analyzed with FlowJo
(Tree Star).
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For YFV infections, transduced fibroblasts were submitted to IFN-β pretreatment
and YF17D infection as described below. Cells were detached after incubation for 10
minutes at room temperature in Accumax (STEMCELL, cat. 07921). Cells were then fixed
in 4% paraformaldehyde for 20 minutes at room temperature prior to permeabilization with
BD perm buffer (BD Biosciences, cat. 554723). BD perm buffer was used for antibody
incubations and washes. Cells were incubated with primary antibodies for 1 hour on ice,
washed, incubated with secondary antibodies for 30 minutes at room temperature, washed,
and resuspended in PBS with 1% FBS prior to analysis using a BD LSRII flow cytometer.
The primary antibody was a mouse anti-YFV (Santa Cruz Biotechnology cat. sc-58083,
RRID:AB_630447) diluted 1:250, while the secondary antibody was a goat anti-mouse
Alexa Fluor 647 (Invitrogen cat. A-21203) diluted 1:1000.
Electrophoretic mobility shift assays
EMSA was performed as previously described174. 25 minutes following
stimulation, cell activation was blocked by incubation with cold 1X PBS, and the cells
were gently lysed to remove cytoplasmic proteins while keeping the nucleus intact. Nuclear
lysis buffer was then added and the recovered nuclear extracts were subjected to
nondenaturing electrophoresis with alexa647 labeled GAS (from the FCγR1 promoter: 5′ATGTATTTCCCAGAAA-3′)

and

ISRE

(from

the

ISG15

promoter:

5′-

GATCGGGAAAGGGAAACCGAAACTGAA-3′) probes. Gels were then imaged on an
Amersham Imager 600 (GE Life Sciences) in the Cy5 channel.
Quantitative RT-PCR
For chapter 2, Total RNA from PBMCs was extracted using RNAqueous-Micro
Kit (Ambio). Reverse transcription was performed using the High-Capacity cDNA Reverse
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Transcription Kit (Applied Biosystems). Messenger RNAs were quantified with IRF9
probes Hs00960976-m1 (exon 1-2) and Hs00196051-m1 (exon 7-8) (Thermo Fischer
Scientific) by qRT-PCR using Taqman Gene Expression Assay (Applied Biosystems) and
normalized to the expression level of HPRT1.
RNA from B-LCLs and SV40-F cells stimulated with 1,000 IU/ml IFN-α2b, IFNβ, or IFN-𝛾 for 2 or 8h, or primary fibroblasts treated for 6h, were lysed with RNA lysis
buffer, treated with DNase, and RNA was purified according to the manufacturer’s
protocol (Zymo Research, Irvine, CA). Reverse transcriptase PCR was performed using
random hexamers and the Superscript III reverse strand synthesis kit according to the
manufacturer’s recommendations (Thermo Fisher Scientific, Springfield Township, NJ).
qRT-PCR was performed with Applied Biosystems Taqman assays using the βglucuronidase (GUS) housekeeping gene for normalization for SV40-F cells, or B-actin for
primary fibroblasts. Results are expressed using the ΔΔCt method, as described by the
manufacturer.
Virus assays
VSV infections
SV40-F cells were infected with vesicular stomatitis virus (VSV) at a multiplicity
of infection (MOI) of 3. The inoculum was absorbed onto the cells for 30 minutes at 25°C,
washed twice with PBS and cultured in DMEM with 10% FBS at 37°C. Virus samples
were collected at the indicated time points. Viral titers were determined by endpoint
dilution on Vero cells using the Reed and Muench calculation175. Where indicated, cells
were pretreated with IFN-α2b for 16h prior to virus infection. Primary fibroblasts were
infected with Indiana stock VSV (MOI=9.3), with or without pretreatment with 10,000
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U/ml IFN-α2b for 24 hours prior to infection. The inoculum was left on the cells, and cell
survival was monitored with Resazurin assay kit (Abcam, catalog number ab112119) at 1,
2, and 3 days post-infection.
IAV and HSV-1 infections
SV40-fibroblasts were infected with influenza virus (A/California/4/2009) as
previously described125. Briefly a viral inoculum was absorbed onto the cells (MOI=0.5)
for 30 minutes at 25°C. Cells were then washed twice with Hank’s balanced salt solution
and cultured at 37°C in the presence of 0.1µg/ml TPCK-trypsin (Sigma-Aldrich, St. Louis,
MO, USA). Virus samples were collected at the indicated times after infection and
influenza titers were determined by plaque assay on MDCK cells. For HSV-1-GFP
infection, SV40-transformed fibroblasts were plated in a 96-well dish and were infected
with HSV-1-GFP (MOI=0.01) in DMEM supplemented with 2% FCS. GFP fluorescence
was then assessed at 0, 8, 24, 48, and 72 hours post infection. HSV-1-GFP was a gift from
Dr. Desai176. For HSV-1 (KOS strain, ATCC), SV40-Fs were seeded at a density of 105
cells per well in a 24 well plate and infected (MOI=0.01) in DMEM + 2% FCS.
Supernatants were collected at the given time points post-infection and TCID50 values were
calculated following the method of Reed and Muench, after inoculation of Vero cells in
96-well plates175.
RSV, PIV and HRV infections
Human rhinovirus HRV-A16 and recombinant respiratory syncytial virus (RSV)
derived from the A2 strain and containing the enhanced GFP, were used as previously
described (Lamborn et al., 2017). rgPIV3, a recombinant human parainfluenza virus type
3 derived from the JS strain and containing the enhanced GFP, was a gift from Dr. Peter
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Collins, NIAID (Zhang et al., 2005). SV40-transformed fibroblasts were seeded at 100,000
cells per well in 12-well tissue culture plates in DMEM-Dulbecco’s Modified Eagle
Medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100
µg/ml streptomycin (all from Invitrogen), and 55 µM 2-ME (Sigma-Aldrich) After
overnight culture, cells were infected with RSV-GFP (MOI 0.5) or PIV3-GFP (MOI 0.1).
At 24 and 48 hours after infection, cells were harvested and flow cytometric detection of
GFP in RSV-infected viable cells was performed as previously described45. Flow
cytometric detection of GFP in PIV3-infected viable cells was performed under similar
conditions. For IRF9 siRNA knockdown experiments, human primary dermal fibroblasts
were transfected with negative siRNA control, Stealth siRNA to IRF9 (Thermo Fisher
Scientific; HSS173591), or siRNA to MAVS (Thermo Fisher Scientific; HSS148537),
using the P3 Primary Cell 96-well Nucleofector kit (Lonza) as described45. 3 d after
transfection, cells were infected with RSV (MOI 0.5), PIV (MOI 0.1), or HRV16 (MOI
10). RSV, PIV, and HRV virus replication were quantitated as described above.
YFV infections
Preparation of virus stocks.
YF17D viral stocks were derived from pACNR-2015FLYF-17Da plasmid, a derivative, to
be fully described elsewhere, of the previously described pANCR-FLYF-Dx containing
the full-length infectious YF17D genome under an SP6 promoter177. In pANCR2015FLYF-17Da, the linearization site for preparation of RNA was changed to AfIII, an
XhoI site within the YF coding region was restored, and adventitious mutations that had
occurred during bacterial propogation of pANCR-FLYF-17Dx in the lab were corrected.
Asibi viral stocks were derived from an analogous full length Asibi cDNA infectious clone
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designated pACNR-2015FLYF-Asibi, to be fully described elsewhere. In vitro-generated
RNA transcripts were electroporated in Huh7.5 cells178. Virus was harvested 24 h after
transfection and titers of 6x105 PFU/ml (17D) and 6x103 FFU/ml (Asibi) were determined
by plaque or focus forming assay on C3 fibroblasts. Single-use aliquots were stored frozen
at –80°C until use.
Infection of cells.
Prior to infection, patient-derived fibroblasts were pretreated with or without 1000 U/ml
IFN-β (PBL Assay Science) for 16 hours. 17D (or Asibi) was then inoculated to
approximately 50,000 (or 20,000) fibroblasts in 24-well (or 48-well plates, respectively).
For 17D infections, media was discarded and cells were incoluated with 250 µl of 17D
diluted in Optimem (MOI=0.05) for 2 h at 37°C. Asibi infections were similar to 17D,
except cells were incoluated with 100 µl of Asibi diluted in Optimem (MOI=0.03). Cells
were then washed twice with culture media and incubated at 37°C with 0.5 ml of fresh
culture media. At the indicated time points post-infection, media containing the virus
produced by the fibroblasts were harvested and titered on Huh7.5 cells by plaque-forming
assay.
Plaque assay.
Harvested media was serially diluted 1:10 in Optimem. Approximately 0.5 million
Huh7.5 cells were inoculated with 400 µl of diluted virus in 6-well plates, for 2 hours at
37°C. After removal of the inoculum, a 3 ml of overlay of 1.2% Avicel in DMEM
supplemented with 1x Pen/Strep and 2% FCS was added and cells were incubated for 3
days (17D) or 4 days (Asibi) at 37°C. After formaldehyde fixation, the cells were stained
with crystal violet and the plaques were enumerated.
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IFN-ß measurement
The concentration of IFN-β in the supernatant of infected cells was measured by
ELISA using the VeriKine-HS™ Human IFN-β Serum ELISA Kit (PBL Assay Science),
according to the manufacturer’s instructions, using 50 µl of media.
ZIKV infections
Infection of cells.
Prior to the infection, the ZIKV stock titer of 1x106 FFU/ml was determined by focus
forming assay on C1 fibroblasts. IFN-β pre-treatment, virus infection (ZIKV MOI=0.05),
and quantification of virus production were conducted on patient-derived fibroblasts as
described above for Asibi, except Vero cells were inoculated with 300 µl of virus for the
plaque-forming assays.
MeV infections
Approximately 50,000 patient-derived SV40-F cells were seeded in 48-well plates
and pretreated or not with 1,000 U/ml IFN-α2b (PBL Assay Science) for 16 hours. Cells
were incubated for one hour at 37°C with measles virus diluted in DMEM with 10% FCS
(MOI=0.1). After virus inoculation, cells were washed twice with PBS and incubated at
37°C with 0.2 ml of fresh culture media. At the indicated timepoints post-infection, media
containing the virus produced by the fibroblasts was harvested and TCID50 values were
calculated following the method of Reed and Muench after inoculation of Vero cells in 96well plates.
VirScan analysis
Patient serum was analyzed by VirScan in two independent experiments as
previously described92. Briefly, an oligonucleotide library encoding 56 amino acid peptides
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tiling across the genomes of 206 viral species was synthesized on a releasable DNA
microarray and cloned into T7 phage. Patient serum containing 2ug of IgG was added to
the phage library and immunoprecipitation was performed with Protein A and G beads.
Enriched peptides were identified by PCR and Illumina sequencing of the peptide cassette
from the immunoprecipitated phage.
mRNA-seq analysis
Total RNA from IFN-a2b-stimulated B-LCL and primary fibroblast cells was
isolated RNeasy kit; QIAGEN) and RNA integrity was assessed on an Agilent 2100
Bioanalyzer (Agilent Technologies). Poly (A)mRNA enrichment and cDNA library
preparation was performed using a TruSeq Stranded mRNA Library Prep Kit (Illumina) in
accordance with the manufacturer's recommendations. Paired-end sequencing was
performed on HiSeq4000 (Illumina) with 150 cycles. Quality control of the raw fastq files
was performed using FastQC179. The samples were then aligned to the reference genome
(Ensembl GRCh37) using STAR aligner180. Aligned output was then converted to BAM
files using SAMtools166. The resulting BAM files were used to quantify the read counts
using the HTseq-count tool181. The output of technical repeats (patient samples that had
been stimulated in duplicate) was found to have a high correlation coefficient (not shown).
Subsequent downstream analysis was carried out in R statistical programming language182.
Read counts of technical repeats were averaged and IFNa2b-responsive transcripts were
identified by comparing stimulated against unstimulated conditions in the three healthy
control subjects, using a minimal 1.5-fold change in expression (up-regulated or downregulated) as cut-off. The response gene list include only those that had satisfied the filter
criteria in all three controls. This resulted in a total of 1064 and 1576 genes that were
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responsive in the IFN-a2b-stimulated B-LCL and primary fibroblasts, respectively. The
gene lists were then used to identify, again using a 1.5-fold change as cut-off, IFN-a2bresponsive and unresponsive genes in the cells of IRF9-, STAT1- and STAT2-deficient
patients. The overall residual responses in the patient's cells were computed by counting
the responsive genes in each patient and cell type and by calculating the percentage out of
the total number of response genes in each cell type. The response in the healthy control
subject was set at 100%.
For B-LCL network analysis, a >5 fold cut-off was applied to the control groups to
generate the target list of IFN-a2b induced genes. From the 749 up-regulated genes in the
healthy controls, 84 were induced at >5 fold. This gene was then used to filter the IRF9deficient patient, using the same >1.5 fold cut-off applied in mRNA-seq analysis. In the
IRF9-deficient patient, a total of 37 genes were found to be induced at >1.5 fold and 47
were non-responsive. These two lists were then entered into Interferome v2.01 and queried
for ISGs, using similar experimental criteria as the current study183. Of the 37 genes found
to be responsive in the IRF9-deficient patient, 24 were identified as ISGs. Of the 47 nonresponsive genes, 39 were identified as ISGs. The combined ISG gene lists for the IRF9deficient patient was used to conduct network analysis in GeneMANIA, using biological
process-based Gene Ontology weighting method and the maximum resultant genes set to
20184. The network was examined using both biological pathway (4.35%) and physical
interactions (67.64%).
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